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Listeria monocytogenes (Lm) is a foodborne pathogen, found ubiquitously in nature, and 
has a high morbidity rate among immunocompromised individuals, the elderly, and 
especially pregnant women and their fetuses resulting in abortion, stillbirth, and neonatal 
infection.  There are currently no preventative medical interventions against Lm 
infection.  The Listeria adhesion protein (LAP) is present in both pathogenic and non-
pathogenic Listeria (i.e., L. innocua) and has shown to interact with host epithelial 
proteins causing tight junction dysregulation aiding in pathogen attachment and 
paracellular translocation across the host intestinal epithelium.  Our lab has demonstrated 
that recombinant probiotics, Lactobacillus casei (LbcWT) expressing LAP from either 
the pathogenic L. monocytogenes (LbcLAPLm) or the nonpathogenic L. innocua 
(LbcLAPLin) prevented Lm attachment in in vitro cell culture experiments.  Here, we 
investigated the beneficial attributes of our recombinant probiotics against clinical 
listerial infection of healthy mice and subclinical listerial infection in pregnant guinea 
pigs (GP).  We supplied animals with freshly prepared wild type (LbcWT) and 
recombinant probiotics (9 ? 109 cfu/ml) in sterile water daily for 10 (mice) or 17 days 
(GP).  They were challenged with a clinical dose (4 ? 108 cfu/mouse) and subclinical 
  
xi  
dose (9 ? 108 or 4.5 ? 109 cfu/GP) of Lm and sacrificed 48 h (mice) or 72 h (GP) post 
challenge.  Organs, tissues, blood, feces and fetuses were collected for Lm presence and 
enumeration. Also, probiotic colonization, short chain fatty acid (SCFA), and serum 
cytokine, cholesterol, and trace mineral profiles were determined.  Histopathological 
samples from the ileum, liver, and mesenteric lymph nodes (MLN) were scored for 
inflammation.  Recombinant probiotics reduced Lm carriage in the challenged mice 3-5 
log.  In the recombinant probiotic-fed GP groups, Lm was present in the maternal liver, 
spleen, and MLN and absent in the maternal blood, kidney, placenta, and fetal liver, 
while LbcWT and Lm control groups showed Lm presence in nearly all tissues tested. 
We found no probiotic bacteria in any extra-intestinal tissues.  Recombinant probiotic-fed 
groups showed a decrease in pro-inflammatory cytokines (TNF?, IL-6, TGF?) in contrast 
to LbcWT and Lm control groups.  Total SCFA content suggests that probiotics helped 
maintain SCFA levels against the detrimental effects of Lm.  Among the trace minerals 
tested, serum calcium and zinc levels were higher (P < 0.05) in recombinant probiotic-fed 
groups than the LbcWT and Lm control groups. Taken together, these data indicate that 
LAP-expressing recombinant probiotics confer anti-listerial effects, participate in 
immune modulation and have a positive impact on overall health in mice and pregnant  
of the population, these recombinant probiotics could confer protection against Lm and 
provide a platform for future research into the use of probiotics as a “probiotic vaccine.” 
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CHAPTER 1.  INTRODUCTION 
 
 
1.1.  Foodborne Pathogens and Disease 
 
Enteric foodborne pathogens continue to be an increasingly severe global health 
concern.  While the total global burden of foodborne illness is very difficult to 
investigate, in the year 2010, the World Health Organization (WHO) estimated that 22 
foodborne pathogens were responsible for  approximately 2 billion illnesses, resulting in 
over 1 million deaths The Centers for Disease Control and Prevention (CDC) estimated  
that, in the United States alone, approximately 48 million cases of foodborne disease 
occur annually, resulting in 128,000 hospitalizations and 3,000 deaths (Scallan et al. 
2011). Foodborne illness outbreak data from 2006 to 2010 revealed that bacterial 
pathogens were responsible for 40% of the outbreaks, norovirus for 49%, chemicals 6%, 
parasites 1%, and other multiple miscellaneous agents were responsible for 4% when 
etiologic agents were known.   There are many bacterial, viral, fungal, and parasitic 
adulterants in the global food supply; however, to be of particular concern to cause 
illness, agents must have the potential to cause significant morbidity and mortality with a 
relatively low infective dose, be ubiquitous in nature, and be able to persist or multiply in 
food.   According to WHO, the major foodborne enteric pathogens include nontyphoidal 
Salmonella, Campylobacter, Shiga-Toxin Producing E. coli (STEC), Listeria, Vibrio and 
Norovirus.  Among the foodborne diseases, the gastrointestinal disorders are most 
predominant resulting in abdominal cramp, nausea, vomiting, diarrhea and dysentery. 
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The disease is caused primarily by Staphylococcus aureus, Bacillus cereus, Cronobacter 
sakazaki, Salmonella enterica, Shigella spp, Vibrio spp, Norovirus, Ebola virus, 
Rotavirus, Entamoeba histolytica, Cryptosporidium, Cyclospora, Giardia, Isospora, 
Taenia spp. and many more. In addition, foodborne pathogens may cause reactive 
arthritis, Reiter’s syndrome, and rheumatoid arthritis, as sequelae to Campylobacter, 
Salmonella, Shigella, and Yersinia infections. Debilitating Guillain Barre Syndrome 
(GBS) can also follow after Campylobacter infection. Hemorrhagic uremic syndrome 
(HUS) and kidney damage can happen due to Shiga toxins produced by STEC and 
Shigella spp. Hepatitis and jaundice are caused by food and waterborne Hepatitis A virus 
(HAV) and Hepatitis E virus (HEV) infections. Pregnancy related complications, 
miscarriage, and stillbirth, neonatal and perinatal infections are due to Listeria 
monocytogenes and Toxoplasma gondii infections. Central nervous system disorder, 
meningitis and menigoencephalitis can be caused by Listeria monocytogenes, bovine 
spongiform encephalopathy (BSE), and Nipha virus. Neurological disorders and paralysis 
may result from consumption of toxins produced by Clostridium botulinum and seafood 
toxins, and from Campylobacter infection. Acute or chronic disease including 
malignancies and auto-immune diseases may result from mycotoxin exposures, and 
allergic responses by seafood toxins such as histamine, saurine cadaverine and other 
small amines. 
Over the last few decades, our understanding of the relationship between the diet 
and general health has evolved from the simplistic perception of primarily only an 
acquisition of nutrients needed for metabolism to a greater understanding of how specific 
foods promote the overall well-being of an individual (e.g., “superfoods,” antioxidants, 
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anti-inflammatories, etc.).  This understanding fostered the use of the term “functional 
foods.”  Foods that, beyond simply providing nutritional value, can benefit additional 
specific functions within the body, are considered functional foods (Figueroa-Gonzalez et 
al. 2011).  Because of their ability to specifically enhance gut health and function, 
probiotics may be considered a functional food (Nagpal et al. 2012).  Probiotics are 
typically nonpathogenic microorganisms that promote health benefits when administered 
in clinically-appropriate dosing.  The most common probiotics are Lactobacillus and 
Bifidobacterium.  To be considered a probiotic, a microorganism must exert benefits in 
three ways: (i) Provide the host with organic acids (short chain fatty acids) through 
anaerobic fermentation of carbohydrates that can be positively utilized by the host.  There 
has been a wealth of recent studies investigating the wide reach of these fermentation end 
products, suggesting that they play a major role in brain function and cognition. (ii) 
Stimulate or prime the host immune system, without causing inflammation within the 
gastrointestinal tract (GIT).  (iii)  Exclude pathogens in the GIT from causing disease by 
outcompeting them for the limited resources and space (Stecher and Hardt 2011). In 
general, probiotics are known to prevent/alleviate chronic inflammatory bowel disease, 
colorectal cancer, metabolic disorders, allergic response, obesity, and osteoporosis 
(Azcarate-Peril et al. 2011; Ly et al. 2011; Amalaradjou and Bhunia 2012; Cate et al. 
2015; Kim et al. 2016). They are also administered in preterm neonates to allow early 
colonization of beneficial microorganisms (Deshpande et al. 2011)   
Further, probiotics must be administered in adequate amounts to be beneficial.  
Widespread colonization of the gut by probiotics can obstruct pathogen access to the 
physical niche required for attachment and infection (Gaggia et al. 2010).  If physical 
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displacement is insufficient and a pathogen is able to colonize, probiotics have several 
functional attributes which allow them to effectively subvert pathogen infections within 
the gut.  Like many microorganisms trying to survive within a complex ecosystem, 
several probiotics can inactivate pathogens through the secretion of antimicrobial 
peptides, called bacteriocins (Klaenhammer 1993; Amalaradjou and Bhunia 2012).  As 
previously stated, probiotics stimulate the host immune system, allowing for a prompt 
host immune response to host-pathogen interaction (Oelschlaeger 2010; Gourbeyre et al. 
2011).  While probiotics appear to be a good candidate to confer protection against 
enteric pathogens, the efficacy of probiotics is often unpredictable and strain specific. 
Using probiotic mitigation of enteric pathogens as a template, while addressing the 
short comings of unpredictability and strain specificity out lab has bioengineered a 
recombinant Lactobacillus casei expressing the Listeria Adhesion Protein (LAP) from both 
pathogenic Listeria monocytogenes (LbcLAPLm) and non-pathogenic Listeria innocua 
(LbcLAPLin).  We have demonstrated the ability of these recombinant probiotics to reduce 
adhesion, invasion, and translocation of L. monocytogenes in vitro (Koo et al 2012; 
Amalardjou et al., in preparation) and their protection against infection in mice.  Here we 
seek to further investigate the efficacy of these probiotics in vivo.  In this thesis we will 
confirm that the recombinant probiotics expressing LAP, especially from L. innocua, 
confer protection against clinical L. monocytogenes infection in mice.  Further, we will 
show that they also protect against infection in pregnant guinea pigs.  We will investigate 
the mechanisms that the probiotics employ to mitigate infection and other general health 






CHAPTER 2.   LITERATURE REVIEW 
 
 
2.1.  Listeria monocytogenes – Foodborne Pathogen 
 
The genus Listeria was termed by Pirie in 1940 to represent all catalase positive, 
Gram-positive rods (Pirie 1940).  There are currently 17 known species of Listeria, which 
are broken into two groups based on genotypic and phenotypic similarities: (i) Listeria 
sensu strictu, L. monocytogenes, L. seeligeri, L. marthii, L. ivanovii, L. welshimeri, and L. 
innocua, and (ii) Listeria sensu lato (discovered after 2009), L. grayi, L. rocourtiae, L. 
weihenstephanensis, L. grandensis, L. riparia, L. booriae, L. fleischmannii, L. 
floridensis, L. aquatica, L. newyorkensis, and L. cornellensis (Orsi et al. 2011; Orsi and 
Wiedmann 2016)  Of these species, only two are pathogens, L. ivanovii and L. 
monocytogenes.  L. ivanovii is an animal pathogen that is particularly important in 
ruminants, while L. monocytogenes is a human pathogen that causes a third of foodborne 
deaths (Scallan et al. 2011).  The health and economic burden related to outbreaks and 
food recalls are high societally and in the food industry (Ivanek et al. 2004).  
  Listeria monocytogenes was first described by E.D.G Murray in 1926 and 
originally named Bacterium monocytogenes; however, when Pirie named the genus of 
catalase positive, gram-positive rods Listeria in 1940, it was reclassified as Listeria 
monocytogenes.  In a natural environment, L. monocytogenes adopts a saprophytic 
lifestyle; however, within mammalian hosts, a set of inducible virulence factors allows 
for establishment of productive infection.  L. monocytogenes can be broken down into 13 
  
8  
different serotypes, with serotypes 1/2a, 1/2b, and 4b cause 96% of human infection; 
however, serotype 4b is associated with the majority of listeriosis outbreaks.  This may be 
due to its higher mobility (Swaminathan and Gerner-Smidt 2007).   
 L. monocytogenes is also grouped into lineages which are based on their ribotype 
patter and virulence genes  (Bhunia 2007).  Lineage I has the highest virulence and is 
associated with most Listeria outbreaks.  Lineage II is the intermediate group associated 
with sporadic outbreaks, while lineage III is not associated with outbreaks (Orsi et al. 
2011) (Orsi and Wiedmann 2016) 
Table 2-1.  Classification of L. monocytogenes by lineage 
Lineage Serotypes Pathogenicity Outbreak characteristics Source 
















II 1/2a, 1/2c, 3a High genetic 
diversity 
Most isolated 
















et al. 1995)  
IV (formerly 
IIIB) 











Exposure to L. monocytogenes occurs via contaminated foods including ready-to-eat deli 
meats, unpasteurized dairy products, and increasingly more frequently raw produce. 
Annually about 1,500 individuals are infected of whom 255 are killed (Scallan et al. 
2011).  
 
2.2.  Epidemiology 
 
A recent surveillance report indicates that between 2009 and 2011, listeriosis had a 
case fatality rate of 21% (CDC 2013). An inconsistent incubation period and clinical 
presentation of listeriosis mimicking viral illness can preclude effective diagnosis and 
result in delayed treatment with increased morbidity and mortality. Advances in 
technology for identifying agents responsible for foodborne outbreaks allow for a rapid 
response once the etiology is determined, but effective therapeutic intervention against L. 
monocytogenes is still precluded by incomplete characterization of the bacterial-host cell 
interaction at the level of the gastrointestinal tract. 
Understanding where a pathogen can survive and multiply, or their reservoirs is 
an essential step in pathogen control.  Unfortunately, Listeria spp. have robust genomes 
allowing for adaption to and survive in many places, including the soil, water, and 
vegetation, but Listeria spp. are primarily associated with soil and decaying vegetables 
(Vivant et al. 2013).   
L. monocytogenes has a host of virulence factors that are expressed to facilitate 
survival, adhesion, invasion, and eventual cell-to-cell spread throughout the body while 
overcoming host immune defense.  These virulence factors are listed in Table 2-1 below, 
and several will be further discussed in successive sections; however, before L. 
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monocytogenes can infect a host, it must gain access to the host through a transmission 
vehicle, primarily food, but, while rare, it is possible to contract L. monocytogenes 
through direct (wounds) and person-to-person contact. 
 
2.3.  Listeriosis – foods, risk factors, and treatment 
 
The disease primarily associated with L. monocytogenes infection is called listeriosis; 
however, it has also been associated with gastroenteritis (Bhunia 2007).  There have been 
many outbreaks involving L. monocytogenes in this decade.  
Table 2-2.  L. monocytogenes outbreaks between 2011 to 2016. 
Year No. of cases No. of fatalities 
 Fatality 
(%) States Vehicle 
2011 147 43 29.3 28 Cantaloupe 
2012 22 4 18.2 14 Ricotta Cheese 
2013 6 1 16.7 5 Cheese 
2014 8 1 12.5 2 Dairy products 
2014 35 7 20 12 Carmel Apples 
2015 10 3 30 4 Ice Cream 
2015 30 3 10 10 Soft Cheese 
2016 19 1 5.3 9 Packaged Salad Mix 
2016 2 1 50 1 Raw Milk 
2016 9 3 33.3 4 Frozen Vegetables 
CDC 
Foods of particular concern for L. monocytogenes contamination are minimally processed 
foods such as hot dogs, deli or lunch meats (especially from the deli counter), pate, 
smoked meats and fish, soft or unpasteurized cheeses (queso fresco); and fresh fruits and 
vegetable such as cantaloupe, apples, spinach, and lettuce.  People that are at an elevated 
risk of systemic listeriosis are individuals with suppressed, compromised, developing, or 
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underdeveloped immune systems.  This high-risk group includes cancer and organ 
transplant patients receiving immunosuppressants, HIV/AIDS patients, very young 
individuals, the elderly, and pregnant women and their fetuses.  Healthy individuals are at 
risk for the rare, gastrointestinal form and are typically infected by consumption post-
processing contaminated foods (Bhunia 2007). 
 
2.4.  Gastrointestinal infection 
 
The self-limiting, gastrointestinal form of L. monocytogenes infection primarily 
affects healthy adults rather than children.  Foods typically associated with these 
outbreaks are smoked fish, cheese, cold rice salads, tuna salad, and corned beef.  
Gastrointestinal infection requires a high infectious dose of 106 - 108 cfu/g.  The 
incubation period is typically 24 hours but can range from 6-10 days.  The mechanism is 
unknown; however, Listeria is not known to produce endotoxins, but rather it is 
suspected that direct invasion and disruption of gastrointestinal cells and mucosa is 
responsible (Ooi and Lorber 2005).  Symptoms that characterize listerial gastroenteritis 
include fever, headache, nausea, abdominal pain, and watery diarrhea. 
 
2.5.  Systemic Listeriosis 
 
Systemic for if L. monocytogenes infection is called listeriosis, a disease with low 
morbidity, but high mortality.  Listeriosis affects immunocompromised individuals 
including, individuals taking immunosuppressant drugs, HIV/AIDs patients, the young, 
the elderly, pregnant women and their fetuses, alcoholics, and individuals who have 
diabetes.  The hallmark of systemic spread is the ability of the bacterium to breach the 
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intestinal barrier and is circulated through blood and the lymphatic system to 
extraintestinal organs and tissues.  Within 24 hours the bacteria can be cultured from the 
liver, mesenteric lymph node, spleen, and gall bladder (Burkholder and Bhunia 2010).  
Without intervention, Listeria can spread and infiltrate the blood-brain and feto-placental 
barriers.  An inconsistent incubation period and clinical presentation of listeriosis 
mimicking viral illness can preclude effective diagnosis and result in delayed treatment 
with increased morbidity and mortality.  In non-pregnant individuals, the systemic 
disease is characterized by fever, headache, malaise, septicemia, meningitis, and liver 
abscess (Bhunia 2007).   
 
2.6.  In utero and placental transmission 
Listeria infection in pregnant women is not particularly detrimental to the mother, 
typically resulting in the gastrointestinal form of infection (symptoms described in 
section 2.3.3); however, when vertically transmitted to the fetus it can result in 
spontaneous abortion, stillbirth, premature labor, or neonatal infection, depending on the 
gestational age (Bakardjiev et al. 2006).  Pregnant women are 18 times more likely to 
have listeriosis than non-pregnant women, while is most likely a product of the 
suppression of cell mediated immunity during pregnancy (Lamont et al. 2011).  Listeria 
infections are difficult to diagnose during pregnancy because only 30% of the known 
cases of maternal L. monocytogenes infections are symptomatic and L. monocytogenes is 
only detectable in blood samples of only 36% of asymptomatic cases (Mylonakis et al. 
2002). Location of neonatal infection is paramount regarding the outcome of the neonatal 
infection and are termed early and late onset.  If the neonate is infected during gestation  
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then and shows septicemia upon birth, it is termed early onset.  If the neonate is 
infected as it breaches the birth canal onset of symptoms occurs about 14 days after birth 
and typically manifests as meningitis (Bhunia 2007).   
 
2.7?  Pathogenesis 
The pathogenesis of several pathogens is dependent on the ability of the pathogen 
to breach host barriers, including the skin and mucosal, epithelial, blood-brain, or 
placental.    Moreover, during the intestinal phase of infection Listeria must survive the 
harsh environment of the gastrointestinal tract, including low pH, bile salts, mucus, 
antimicrobial peptides, and the host gut microbiome.  The pathogen responds to these 
environments through stress genes regulated primarily by PrfA and Sigma B (Xayarath 
and Freitag 2012).  The pathogenesis of L. monocytogenes is dependent on the invasion 
of the gut epithelial barrier where it has access to several tissues through the bloodstream, 
invasion of the blood-brain barrier where it can cause meningitis, and, in the case of 
pregnant women, invasion of the placental barrier where it can cause abortion or neonatal 
infection.  The critical step in L. monocytogenes systemic pathogenesis is breaching the 
intestinal barrier, which includes passive invasion through professional phagocytes and 
active intracellular and paracellular invasion of non-phagocytic epithelial cells. 
L. monocytogenes has many virulence genes responsible for intestinal infection and 
subsequent dissemination. These include genes responsible for the expression of  
internalins (inlA, inlC, inlJ), listeriolysin O (LLO encoded by hly, actin polymerization 
protein (actA), phosphatidyl-inositol-phospholipase C (PI-PLC encoded by plcA), 
invasion-associated protein (iap), and virulence regulator (encoded by prfA) have been 
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reported as the most important virulence factors for L. monocytogenes (Camejo et al. 
2011; Poulsen and Czuprynski 2013).  Most of these genes are located in a particular 
section of the genome calls the Listeria Pathogenicity Island (LPI-1) (Gahan and Hill 
2014). 
 
Table 2-3.  Listeria monocytogenes virulence factors 
Virulence Factor Size (kDa) Receptor Function 
Internalin A (InlA) 88 E-cadherin 
Epithelial attachment and 
invasion at gut and feto-placental 
barrier 
Internalin B (InlB) 65 Met, gC1q-R/p32 
Epithelial attachment to 
hepatocytes 
Listeria adhesion 
protein (LAP) 104 Hsp60 
Adhesion and invasion to 










90 - cytoplasmic movement within host cell via actin polymerization 
Phospholipase C 
(PI-PLC, PC-PLC) 29-33 - 





 Gp96 (ER) Adhesin 
Autolysin amidase 





Metalloprotease 29 - Synthesis of PLC 
p60 50 - Adhesin 
Protein regulatory 
factor (PrfA) 27 - 
Master virulence regulatory 
protein 






2.7.1.? Microfold (M) cells 
Homeostasis between the gut microbial community and the host immune system 
is an important part of human health (Thaiss et al. 2016).  There are centers of immune 
cells in the gastrointestinal tract that considered gastrointestinal-associated lymphoid 
tissue (GALT), which include the Peyer’s patch.  M cells make up 10% of the epithelial 
cells overlaying the intestinal lymphoid tissues (Kanaya et al. 2012; Tahoun et al. 2012).  
These cells differ physically from their epithelial neighboring cells morphologically, 
displaying a diminished brush border and significantly fewer microvilli (Tahoun et al. 
2012).  M-cells also differ functionally, they are highly specialized phagocytic cells that 
capture luminal bacteria from the intestines and present it to the immune cells located 
below in the Peyer’s Patch, including lymphocytes, macrophages, and dendritic cells 
(Lelouard et al. 2012).  M cells do not display specific phagocytosis, but rather uptake 
any commensal or transient cells regardless of pathogenicity (Hase et al. 2009).  Through 
uptake by M cells (passive translocation), L. monocytogenes is able to breach the 
intestinal epithelial barrier.  Once the pathogen is presented to the immune cells it 
expresses a set of virulence factors that allow it to escape phagocytosis and spread cell to 
cell (Beauregard et al. 1997).  This will be discussed further in section 2.4.5. 
 
??????? Intracellular invasion via InlA?
?
Internalins are extracellular adhesion molecules that assist in adhesion and 
invasion of L. monocytogenes.  Twenty-four internalins have been identified in L. 
monocytogenes EGDe strain, but the mechanisms in which they all contribute to 
pathogenesis is yet to be elucidated (Seveau et al. 2007).  There are two internalins, A 
(InlA) and B (InlB) that have been significantly studied and are well understood.  
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Nineteen of the 24 internalins, including InlA and InlB possess N-terminal leucine-rich 
repeat regions (LRRs), which allow for binding between bacterial Internalin and its 
respective host receptor (Schubert et al. 2002). 
InlA has been a very important virulence factor and integral one of L. 
monocytogenes mechanisms for the invasion of non-phagocytic intestinal epithelial cells 
(Lecuit et al. 2004).  E-cadherin, a transmembrane protein that helps fortify the adherens 
junction acts as the intestinal epithelial InlA receptor (Mengaud et al. 1996).  E-cadherin 
is functionally significant for the maintenance of the cell-cell junction integrity in the 
intestines.  The intracellular domain of E-cadherin interacts with cytoskeletal catenin, 
while the extracellular domain homophilically interacts with the extracellular domain of 
E-cadherin on the adjacent cell (Perez-Moreno et al. 2003), resulting in the adherens 
junction.  Interestingly, E-cadherin is located on the basolateral side of the polar intestinal 
epithelial cell and is inaccessible to luminal L. monocytogenes, suggesting that the 
interaction cannot take place in the native anatomical location.  Pentecost et al. (2006) 
reported that as new enterocytes replaced senescent cells, E-cadherin is exposed on the 
tip off villous structures allowing the interaction between InlA and E-cadherin (Pentecost 
et al. 2006).  Binding of InlA to the extracellular domain of E-cadherin results in the 
recruitment of ?-catenin cytoplasmic domain of E-cadherin, which subsequently recruits 
?-catenin which acts as an anchor holding the entire InlA/E-cadherin/?-catenin complex 
host cytoskeletal F-actin (Lecuit et al. 2000). AEHGAP10, a Rho GTPase, facilitates the 
recruitment of ?- catenin to the adherens junction and in turn, Arp2/3 complex regulation  
of  actin cytoskeleton dynamics, and the invagination of the pathogen into the host cell 
(Sousa et al. 2005). 
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2.7.3.? Intracellular invasion via Internalin B (InlB) 
Internalin B belongs to the internalin family of proteins and facilitates intacellular 
translocation of L. monocytogenes in many cell types, but most importantly hepatocytes 
(Braun et al. 1998; Braun et al. 2000).  Rather than being covalently anchored to the cell 
wall, InlBs C-terminus electrostatically interacts with lipoteichoic acid (Bierne and 
Cossart 2007).  InlB binds to multiple host receptors; however, the most relevant is the 
hepatocyte growth factor receptor (Met) (Shen et al. 2000).  Though g1CqR is a receptor 
for InlB, the interaction between the two is insufficient for bacterial invasion of guinea 
pig cell lines, suggesting that invasion via InlB is Met dependent (Khelef et al. 2006).   
Met, a tyrosine kinase that is the receptor for binding hepatocyte growth factor 
(HGF), which is part of the cellular proliferation pathway (Birchmeier et al. 2003).  
Though InlB and HGF bind to the same receptor, they are not competitive and bind to 
different and distinct epitopes of Met (Shen et al. 2000).  Met is a heterodimer composed  
of 45 kDa ? and 145 kDa ? subunits. The extracellular domain includes the N-terminus of 
the ? subunit and the ? subunit, while the cytoplasmic domain consists of the rest of the 
?.  Phosphorylation of the cytoplasmic domain tyrosine molecules leads to downstream 
signaling events (Birchmeier et al. 2003), including activation of phosphatidyl 3-kinase 
(PI3-K) and Ras- mitogen-activated protein kinase (MAPK) pathways (Ireton et al. 1996; 
Shen et al. 2000; Ireton 2013).  Recruitment of Arp2/3 is facilitated by both the PI3-K 
and Ras-MAPK pathways.  Actin remodeling is dependent on the type of host cell and  it 
involves Wiskott–Aldrich syndrome protein (WASP), including WASP (N-WASP) and 
WAVE (Bierne et al. 2005; Hamon et al. 2006). Ena/VASP, responsible for elongating 




assisted by cofilin (Bierne et al. 2005; Hamon et al. 2006), which sis implicated in 
clathrin-mediated endocytosis (Marmor and Yarden 2004; Veiga and Cossart 2005; 
Seveau et al. 2007).  
 
2.7.4.? Paracellular translocation via LAP 
The Listeria Adhesion Protein (LAP: 104 kDa) has been identified as a 
noncanonical L. monocytogenes virulence factor. LAP is a bacterial bifunctional alcohol 
acetaldehyde dehydrogenase (Aad) enzyme encoded by lmo 1634 gene that can be 
identified intracellularly, in the cell wall, and is secreted from L. monocytogenes (Kim et 
al. 2006).  LAP is secreted through the alternate secretory pathway SecA2 and re-
associates with the bacterial cell through a mechanism currently being elucidated 
(Burkholder et al. 2010). Cytoplasmically, LAP is a housekeeping enzyme implicated in 
glycolysis under anaerobic conditions; however, it also moonlights as a cell wall 
anchored adhesion factor in L. monocytogenes. LAP was identified as a bi-functional 
enzyme which consists of an N terminal NAD dependent aldehyde dehydorgenase 
(ALDH) and a C terminal alcohol dehydrogenase (ADH) domain (Jagadeesan et al. 
2010).     
Epitope masking of whole L. monocytogenes cell by monoclonal antibody MabH7 
identified LAP as an adhesin for intestinal cell lines (Pandiripally et al. 1998, Jaradat et 
al. 2003). Importantly, the was confirmed using a LAP insertion mutant KB208, which 
showed reduced adhesion to ileo-cecal HCT8 and enterocyte like Caco-2 cells and 
rescued by the expression of LAP episomally in the LAP deficient mutant (Kim et al. 
2004).  This was further confirmed by expressing LAP in a recombinant Escherichia coli, 
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which exhibited increased binding to Caco-2 cells compared to the wild-type E. coli.  
Taken together, these data suggest that LAP is a prominent listeria adhesion molecule. 
In vitro cell based, molecular, and biochemical study identified surface expressed 
host-cell Heat shock protein 60 (Hsp60) as the host receptor for LAP (Wampler er al 
2004, Jagadeesan 2010, Burkholder and Bhunia 2010). Both transposon and isogenic 
directed plasmid insertional LAP-deficient mutants have been tested against the wild-type 
parental strain, and all LAP mutants exert diminished adhesion to Caco-2 cells and 
attenuated pathogenic effect both in vitro and in vivo murine models (Pandiripally et al 
1999; Jaradat et al 2003; Kim et al 2006; Burkholder et al 2009). Using in vitro cell 
assays, adhesion to Caco-2 cells and subsequent NF-?B activation was diminished in the 
absence of LAP by genetic manipulation, knockdown of host Hsp60 by RNAi, or by 
blockade of host Hsp60 by monoclonal antibody (Wampler et al 2004; Burkholder and 
Bhunia 2010; Drolia et al 2016). Orally dosed murine models demonstrate an attenuated 
capacity for both disseminated infection and a reduced insult to intestinal epithelial 
integrity by the LAP-deficient mutant compared to both the wild type and Internalin A 
deficient strains (Burkholder et al 2009; Drolia et al 2016). In the most recent study, 
using both purified recombinant proteins as well as wild-type and LAP-deficient L. 
monocytogenes, LAP-Hsp60 interaction was shown to be important for activation of NF-
?B activity, MLCK-mediated cellular junction disruption, and to result in increased 
paracellular migration of L. monocytogenes across Caco-2 monolayers (Drolia et al 
2016). Taken together, this evidence strongly suggests a direct role for LAP-Hsp60 
interaction in the enteric phase of infection. 
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Hsp60 is a ubiquitous evolutionary conserved chaperone protein.  Cytosolic 
Hsp60 has been shown to positively regulate NF?B activation via direct interaction with 
IKK?/? (Chun et al 2010) and may be involved in pre-apoptotic signaling (Zhu et al 
2016). Additionally, and uncoupled from its chaperone function, surface expression and 
secretion of Hsp60 in various cells types has been well described. It has been established 
that Hsp60 is able to  act as a receptor for Staphylococcus aureus fibronectin binding 
protein A (FbpA) resulting in internalization (Dziewanowska et al., 2000). 
 
2.7.5.? Extraintestinal dissemination and cell-to-cell spread 
Whether actively or passively, once L. monocytogenes has translocated across the 
epithelial barrier it then spreads to extracellular tissues including the liver, spleen, 
mesenteric lymph node, gall bladder, and lungs via blood circulation and the limbic 
system to cause systemic listeriosis.  To do so it must be able to escape phagocytic 
immune cells, multiply intracellularly, facilitate movement through the cytoplasm to the 
cell membrane, and enter adjacent cells allowing the pathogen to move from cell to cell.  
Upon entry into the host cell the bacteria secrete listeriolysin O (LLO), a cholesterol 
dependent lysin that allows that bacteria to escape the vacuole or phagasome (Henry et al. 
2006; Shaughnessy and Swanson 2007).  In addition to LLO, L. monocytogenes 
expresses Phosphatidylinositol-specific phospholipase C (PI-PLC) that also aids in 
phagosome escape (Camilli et al. 1991).  Upon secretion of these virulence factors, 
especially LLO and the rapid acidification of the vacuole after L, monocytogenes 
invasion the vacuole become permeable and the bacteria is able to escape (Beauregard et 
al. 1997).  Because LLO is indispensable to phagosome escape and the receptor is 
cholesterol, it is hypothesized that LLO is directly responsible for the perforation 
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(Wadsworth and Goldfine 1999).  It is important to note that in nonphagacytic cells LLO 
is not necessary for vacuole escape.  LLO deficient mutants show a 2 fold reduction in 
vacuole escape, but in the absence of LLO the mutant cells secrete a multitude of broad-
range phospholipase c (PC-PLC) and metalloprotease to facilitate escape (Gründling et 
al. 2003).   
Once in the cytoplasm L. monocytogenes multiplies and is able to move through 
the host cell by inducing actin filament rearrangement and polymerization with cell 
surface protein, ActA (Tilney and Portnoy 1989; Tilney et al. 1990).  Interestingly, the N-
terminal domain of ActA is sufficient to induce cytoskeletal rearrangement independent 
of other bacterial determinants (Kocks et al. 1992; Lasa et al. 1997).  The ActA has a 
centrally located domain modulates direction and speed of movement through the cell.  
This domain is composed of four proline-rich repeats that binds proteins of the VASP 
family that activates the Arp2/3 complex inducing actin polymerization, mimicking 
proteins of the WASP family inducing a branched filament actin tail (Geese et al. 2002; 
Auerbuch et al. 2003; Gouin et al. 2005).   
2.7.6.? Feto-Placental barrier 
Listeria monocytogenes is an important cause of maternal-fetal infections and 
serves as a model organism to study these important but poorly understood events.  To 
breach the feto-placental barrier the bacteria must employ similar tactics as breaching the 
intestinal barrier: direct invasion and cell to cell spread; however, the contribution of 
these two tactics are not well understood.  To understand how the bacteria, cross the feto-
placental barrier it is important to understand how the fetal and maternal tissues interact. 
  Humans and guinea pigs have a hemomonochorial placenta, in which maternal 
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blood from uterine lining flows in surrounds fetal villous cells. The maternal blood come 
in contact with fetal syncytotrophoblasts that continuously line the villous surface.  
Branched microvilli make up the apical side of the syncytotrophoblast layer and facilitate 
vertical gas and nutrient exchange (Benirschke et al. 2006; Benirschke et al. 2012).  
These microvilli consist of intermingling immune and cytotrophoblast cells and have 
extra-villus extensions that anchor the fetus to the placenta (Robbins et al. 2010).  These 
cytotrophoblast cells have abundant E-cadherin.  In vitro cytotrophoblast studies have 
shown that InlA deficient strains have 100-fold reduction in invasion (Lecuit et al. 2004), 
suggesting that InlA play a role in barrier breach; however, in vivo these cells are not 
readily accessible by the maternal blood.  Furthermore, InlA and InlB mutants do not 
show a reduction in fetal invasion in guinea pig and mouse models (Wollert et al. 2007; 
Disson et al. 2008).  A study by Ribbons et al. (2010) suggests that syncytotrophoblast, 
the major source of maternal/placental tissue interaction is very resistant to L. 
monocytogenes, but the extra-villous anchoring cytotrophoblasts that are the primary site 
of entry (Robbins et al. 2010). 
 
2.8.? Probiotics 
The term probiotic is derived from the words “pro” and “bios,” meaning “for life.”  
In the early 20th century, Eli Metchnikoff, Nobel Prize winner and grandfather of modern 
probiotics, observed that lactic acid bacteria (LAB) played a positive role in both 
digestion and the immune system.  Metchnikoff believed that with adequate consumption 
of appropriate foods, these “good bacteria” could displace “bad bacteria” within the gut 
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(Mackowiak 2013).  Since the discovery that certain “good bacteria” can confer health 
benefits, there has been a wealth of probiotic research into a wide variety of areas  
(ranging from protection against bacterial pathogens and viral infection to cancer 
prevention, attempting to exploit these microbes for human benefit (Sanders et al. 2013; 
Sanders et al. 2014).   
 
2.8.1.? Definitions 
There have been many iterations of the definition of probiotics over the years; 
however, in 2001, FAO/WHO (2002) (FAO/WHO 2002) defined probiotics as “live 
microorganisms that, when administered in adequate amounts confer health benefits on 
the host” (Hill et al. 2014).  Notably, this definition fails to address the probiotic 
mechanism of action (i.e., balancing intestinal microbiota, immunomodulation, etc.) that 
previous definitions included.  The change in definition was to accommodate the claim 
that certain organisms are probiotic, while not fully elucidating the mechanism by which 
the health benefit is conferred (Sanders 2008).  
Probiotics are divergently categorized based on their ability to colonize the 
intestinal tract.  Resident strains (e.g., Lactobacillus spp.) are commonly found in the 
human gut flora and, when supplemented, can readily colonize the human GIT.  Transient 
strains (e.g., Bifidobacterium spp.) cannot establish themselves within the GIT and are 
excreted by the host.  The duration of residence within the host is both strain- and host-
specific.  The ability of a probiotic to confer its health benefits is dependent on many 
factors, including strain specificity, host microbiome profile, mode of application (e.g., 
capsule, kefir, or yogurt), and ecology of the supplement (monoculture or mixture). 
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Prebiotics, which will be addressed later in this chapter, are sometimes included with the 
probiotic to enhance the probiotic activity of the strain or strains.   
Like all microorganisms, probiotics are identified taxonomically by their genus, 
species, and strain.  Over the past few decades, however, many probiotic species have 
been identified, most of which are Gram-positive, bile-resistant lactic acid bacteria 
(LAB).  The most important genera include Lactobacillus, Lactococcus, Enterococcus, 
 Streptococcus, Pediococcus, Leuconostoc and Bifidobacterium, while the most common 
types used are Lactobacillus and Bifidobacterium (Volzing et al. 2013; Didari et al. 
2014).   
Table 2-4.  Commonly used probiotics 





VSL#3: Streptococcus thermophilus, Bifidobacterium 
breve, Bifidobacterium longum, Bifidobacterium 
infantis, Lactobacillus acidophilus, Lactobacillus 


















Ecologic 641: L. acidophilus, L. casie, L. lactis, B. 





Bio-three: Enterococcus faecalis T-110, Clostridium 
butyricum TO-A, Bacillus mesemtericus TO-A 
Bifidobacterium 
animalis Lactobacillus kefir 
Streptococcus 
faecalis Lactobacillus delbrueckii 
Streptococcus 
faecium Lactobacillus plantarum 
Saccharomyces 
boulardii Lactobacillus grasseri 
 Lactobacillus reuteri 
 Enterococcus faecium 
 Streptococcus lactis 




To be considered a probiotic, microbes must meet certain criteria  (Hill et al. 
2014).  Table 2-6 denotes the notable characteristics of probiotics, but generally a 
probiotic must be Generally Recognized as Safe (GRAS), able to survive in the low pH 
environment of the stomach and be resistant to bile and pancreatic juices, persist in the 
gut, confer general health benefits to the host, and be maintained stably during 
processing, storage, and application. 
 
Table 2-5. Criteria of an ideal probiotic 
•? Accurate taxonomic identification  
•? Accurate antibiotics resistant/sensitivity profile 
•? Able to colonize host (transient or resident) 
•? Generally recognized as safe (GRAS) 
•? Maintain viability in host physiological conditions (bile, hydrochloric acid, pancreatic 
juice, high and low pH of the intestines and stomach) 
•? Persistence in host GIT 
•? Adherence to receptors in host intestinal epithelium 
•? Immunostimulation and immunimodulation activity 
•? Nonpathogenic 
•? Maintain antimicrobial activity at target site 
•? Maintain cell viability at target site 
•? Inability to exchange genetic information (genetic stability) 
•? Maintain viability a activity during processing, storage, and delivery 
Adapted from Amalaradjou and Bhunia, 2012 
 
 
2.8.2.? General health benefits of probiotic bacteria 
Probiotics can be administered in a variety of ways, in either mixed or 
monoculture.  They can be consumed as a supplement in pill or capsule form, or in foods 
including fermented milk (kefir or yogurt), smoothie drinks, fruit juices, wine, chocolate, 
fermented sausage, fresh sauerkraut or fresh pickles, and cheeses. There has recently 
been an increase in probiotic-containing yogurt used to coat an assortment of nutritional 
supplement bars, dried fruits, pretzels, and a host of “healthy” desserts.  An effective dose 
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of probiotics must include a minimum of 5 billion colony-forming units of probiotic 
bacteria (CFU)/day that administered daily for a period of 5 days provides health benefits 
(Gronlund et al. 1999; Williams 2010).  It is generally understood that the health benefits 
of the gut microbiome are due to a synergistic effect among the strains within the biome, 
and this synergistic effect can be extended to the probiotic culture, thus, mixed cultures 
tend to confer greater benefits than monocultures.   
 While many probiotics confer health benefits; the benefits and mechanism of 
action are strain-specific and may not be applicable for all probiotics (Hill et al. 2014).  
Lactobacillus, for example, elicits variable cytokine profiles that are dependent upon the 
species and strain administered (Christensen et al. 2002; Latvala et al. 2008; Vissers et al. 
2010).  The health benefits of probiotics have been well documented by a wealth of 
published research results (Williams 2010; Nagpal et al. 2012; Shen-Shih and Tzu-Ming 
2012) that include food digestion and nutrient metabolism, short-chain fatty acid (SCFA) 
production through carbohydrate fermentation, cholesterol reduction, mucoidal immune 
modulation, enhanced mucus production within the GIT, antimicrobial peptide 
production, enhancement of epithelial barrier integrity, and equilibration of host gut 
microbiota. 
 
2.8.3.? The safety of probiotics therapy 
Bacteria have been added to food for many years to enhance flavor, produce texture 
changes, and provide specific health benefits.  They are added to food pre-production 
(starter cultures) as well as post-production (functional food additives).  When probiotics 
are added to prevent or treat enteric pathogenic disease, the probiotic itself must be 
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nonpathogenic to the host.  Commonly-used probiotic lactic acid bacteria (e.g., 
Lactococcus, Lactobacillus, and Bifidobacterium) are Generally Regarded as Safe 
(GRAS); however, some strains have been known to be opportunistic human pathogens 
in individuals with underlying, immunocompromising health conditions (Boyle et al. 
2006).  Despite these findings, there have been few systematic safety studies performed.   
The Agency for Healthcare Research and Quality (AHRQ) released a study in 2011 
(Hempel et al. 2011) seeking to evaluate the potential health risks of probiotic 
administration.  Within this review, they evaluated 622 studies of probiotic 
microorganisms and concluded that, while there was no apparent elevated risk of human 
illness due to supplementation with the probiotic bacteria administered in these studies, 
there is a significant lack of investigation of potential risk factors associated with 
probiotic supplementation within probiotic studies in current literature.  In summation, 
the study found that current literature was unable to address safety concerns regarding 
probiotic supplementation. The WHO/FAO released a report in 2002, which suggested 
that there are four potential side effects of probiotics: (A) translocation to the 
bloodstream, leading to systemic effects, (B) “deleterious metabolic activities,” (C) 
overstimulation of the host immune system, and (D) gene transfer to commensal 
microbiota, leading to an adverse effect within the gut microbiota or directly to the host, 
such as transfer of antibiotic resistance genes to opportunistic pathogens commonly 
found in the gut microbiome or overproduction of lactic acid leading to lactic acidosis in 
the patient (Doron and Snydman 2015).  Given this, and the strain specificity of probiotic 
action, it is important to screen potential probiotics for the presence of virulence factors, 
antimicrobial resistance, antibiotic sensitivity and antibiotic gene transfer, as well as the 
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potential for the uptake of pathogenic virulence genes (Amalaradjou and Bhunia 2012; 
Didari et al. 2014).  It is important to note that while these complications might occur in 
certain rare and isolated settings, the transient nature of probiotics in the GIT decreases 
the likelihood that they will occur.  Both the Scientific Committee on Animal Nutrition 
(SCAN) and the FAO have developed guidelines for probiotic additives to animal feed 
and food consumed by humans, respectively.  Both strategies employ methods that test 
for the aforementioned factors of safety risk (i.e., genotypic and phenotypic analyses for 
virulence factors, antimicrobial resistance, gene transfer, etc.), with a notable exception, 
that the FAO also requires probiotics to pass double blind, randomized, placebo-
controlled human clinical trials. Within these studies and reviews two areas of probiotic 
used have been identified, probiotic use for the general public through food additives and 
dietary supplements and probiotic use on an individual basis for health intervention as a 
drug or vaccine.  The risk assessment for general use of probiotics as a food additive or 
dietary supplement reveals that the potential risks (lactic acidosis, persistent gut 
inflammation, and antibiotic resistant gene transfer to potential pathogens) are greater 
than the potential general health benefits (gut microbiome balance or flavor 
enhancement).  When probiotics are used on an individual basis to treat specific health 
problems, such as enteric pathogens, acute infectious and antibiotic associated diarrhea, 
and irritable bowel syndrome, the potential risks are balanced by the specific health 






Table 2-6. Proposed probiotic mechanisms of action against human health conditions and 
benefits 
Health condition or 
benefit Proposed Mechanism 
Enteric pathogen resistance 
Antagonism 
Increased antibody production 
Colonization resistance 
Limiting access of enteric pathogens (pH control by acid 
production, bacteriocins, antimicrobial peptides) 
Modulation of tight junction integrity, production of SCFA 
Aid in lactose metabolism Bacterial lactase acts on lactose in the small intestines 
Small bowel bacteria 
overgrowth 
Decrease toxic metabolite production 
Normalize small bowel flora 
 
Antimicrobial activity 
Immune system modulation 
Production of SCFA 
Regulate Th1/Th2 cell activation 
Modulate IL-10/IL-12/IL-6 activity 
Stimulation from phagocytic and dendrocytic cytokines 
Anticolon cancer effect 
Anti-mutagentic and anti-carcinogenic activity 
Detoxification of carcinogenic metabolites 
Immune stimulation and modulation 
Toxic microbial metabolite 
production 
modulation of host microbiota increases carbohydrate 
metabolism of the community 
Antiallergenic activity 
Prevention of antigen translocation into blood stream 
Modulation of immune response to increase in antigen 
Heart disease, blood lipids 
Uptake of cholesterol by gut microflora 





Modulation of urogenital microflora 
Necrotizing enterocolitis Reduce IL-8 response 
Rotovirus gastroenteritis Increased viral specific IgA response 
Inflammatory bowel disease  
Enhance mucosal barrier function 
Decreased inflammatory response 
Immune modulation 
Crohn's disease 





Modulation of urogenital flora 
Regulation of mucosal T-cell populations,  
Mucosal immune stimulation and modulation 





2.9.? Probiotic mechanisms of action 
Several mechanisms of probiotic action have been proposed (Table 2-6); several, of 
which, are discussed in this section.  
 
2.9.1.? Antimicrobial activity of probiotic bacteria 
Microorganisms have evolved to express several antimicrobial properties to improve 
their ability to compete for limited ecological recourses, and probiotic bacteria are no 
exception (Amalaradjou and Bhunia 2012).  Within the ecology of the human GIT, 
probiotics express these antimicrobial factors to enhance their survival and, inadvertently, 
enhance host protection against enteric pathogens.  Probiotics suppress enteric pathogens 
both directly and indirectly through the production of antimicrobial factors and 
modulation of host cell expression of antimicrobial peptides, respectively.   
The secretion of SCFAs by both probiotic and commensal gut microflora provide 
several positive effects on host endocytes and the gut microbiota themselves, including 
antimicrobial effects against enteric pathogens.  SCFA have the ability to disrupt the 
outer membrane of Gram-negative pathogens (e.g., Salmonella enterica serovar 
Typhimurium and various E. coli strains) by inhibiting growth, disrupting osmotic 
pressure and increasing permeability to other antimicrobial factors, produced by both 
probiotic bacteria and host cells that can disrupt pathogen cell membranes (Alakomi et al. 
2000).  Aside from direct bacteriostatic or bactericidal properties, the SCFA’s propionic 
and hexanoic acid promote host antimicrobial production (Alva-Murillo et al. 2012).  
Oral administration of butyrate can possibly stimulate host defense peptides leading to 
the clearance of Salmonella (Sunkara et al. 2012).  Interestingly, SCFA-producing 
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bacteria are apparently immune to the antimicrobial effect of SCFAs, providing them an 
additional selective advantage within the ecology of the gut microbiota (Alva-Murillo et 
al. 2012).  SCFAs produced by probiotic bacteria reduce the pH of the intestinal lumen 
thereby inactivating several enteric pathogens (Carey et al. 2008), and SCFAs also 
regulate colonic T reg cell homeostasis for improved gut health (Smith et al. 2013)   
 Bacteriocins and microcins are antimicrobial agents commonly secreted by Gram-
positive and Gram-negative bacteria, respectively.  Bacteriocins are a heterogeneous 
group of secretory molecules that bind to species-specific extracellular receptors on 
enteric bacteria (sensu lato), including pathogens, that cause morphological (typically 
pore formation) or metabolic changes leading to cell death (Bhunia et al. 1991; Jack et al. 
1995; Daw and Falkiner 1996).  Depending on the molecular weight and the inhibitory 
spectrum of bacteriocins, there are four general classes of bacteriocins produced by lactic 
acid bacteria (Klaenhammer 1993; Cotter et al. 2005).  In contrast, microcins are 
antimicrobial peptides that target the enzymes involved in DNA, RNA, and protein 
structure and synthesis (Duquesne et al. 2007).  There have been many studies in the past 
two decades elucidating the bactericidal or bacteriostatic activities of bacteriocins 
produced by probiotic bacteria.  Lactobacillus acidophilus, a commonly used and 
commercially-available probiotic, can inhibit Salmonella, Shigella, Pseudomonas, and 
Vibrio species in vitro, likely by the inhibitory activity of the bacteriocin, acidophilin 
(Vila et al. 2010; Brown 2011).  A bacteriocin secreted by L. plantarum has broad 
spectrum inhibitory activities against both Gram-positive and Gram-negative bacteria, 
including many pathogens such as S. aureus, L. monocytogenes, and many E. coli strains 
(Kumar Tiwari and Sheela 2008).  A broad spectrum bacteriocin (ABP-118) secreted by 
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L. salivarius UCC 118, although ineffective against other Lactobacillus species, is highly 
inhibitory to Listeria, Bacillus, and Staphylococcus (Dunne et al. 2001; Flynn et al. 
2002).  In further in vivo studies, a mutant strain of L. salivarius was unable to produce 
ABP-118 and had no protection against L. monocytogenes infection, whereas the WT 
control probiotic conferred protection (Corr et al. 2007; Sherman et al. 2009).   
 Some probiotic bacteria also directly exert their antimicrobial properties by 
adhering to the host intestinal epithelial cells and effectively reducing pathogen 
adherence (Collado et al. 2009).  Several in vitro studies involving pretreatment with 
individual strains of Lactobacillus species (viz., L. acidophilus, L. rhamnosus, L. 
helveticus, and L. paracasei) revealed the successful inhibition of adhesion and 
translocation of several pathogens, including enterohemorrhagic E. coli (EHEC), 
enteropathogenic E. coli (EPEC), L. monocytogenes, and Salmonella spp. (Zareie et al. 
2006; Johnson-Henry et al. 2008; Medellin-Pena and Griffiths 2009).   
 Alternatively, probiotic bacteria can indirectly suppress enteric pathogen function 
by eliciting an enhanced antimicrobial response by the host intestinal cells.  The two 
major classes of antimicrobial peptides produced by human intestinal cells are defensins 
and cathelicidins.  Although cathelicidins are constitutively produced in the human GIT, 
butyrate produced by both commensal and probiotic bacteria can also induce cathelicidin 
production (Schauber et al. 2003; Sunkara et al. 2011).  Prophylactic oral administration 
of butyrate has been used to reduce and control both Salmonella (Fernandez-Rubio et al. 
2009) and Shigella infections (Raqib et al. 2006). 
 Human intestinal Paneth cells and neutrophils constitutively secrete ?-defensin, 
while various other epithelial cells constitutively secrete ?-defensin.  Defensins have 
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antimicrobial properties and are produced in the intestine to suppress enteric pathogens 
(Kudryashova et al. 2015).  Several studies have revealed that probiotic bacteria (e.g., E. 
coli Nissle 1917, E. coli DSM 17252, and VSL#3 consisting of four strains of lactobacilli 
(Lactobacillus casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 
three strains of bifidobacteria (Bifidobacterium longum, B. breve, and B. infantis), and 
Streptococcus salivarius subsp. thermophilus) can induce the secretion of  
?-defensins (Wehkamp et al. 2004; Schlee et al. 2007; Schlee et al. 2008; Seo et al. 
2012).  In studies with the probiotic E. coli Nissle, one of the best characterized 
probiotics, human ?-defensin-2 was determined to be flagellin-mediated (Seo et al. 
2012). 
 
2.9.2.? Immunomodulation by probiotic bacteria 
The intestine is an important mucosal organ responsible for the absorption of 
nutrients from digested food; however, the GIT is also a prominent immune organ 
consisting of approximately half of the immune cells in the human body.  It was 
suggested in the 1970’s that the commensal bacteria of the gut play an important role in 
immune modulation as the IgG response to antigens was found to be much lower in 
germ-free (GF) mice than in conventional (CV) mice (Ohwaki et al. 1977).  Additionally, 
it has been revealed that the presence of gut microbiota markedly influences CD4+ and 
CD8+ cell pools within gut-associated lymphoid tissue (GALT) (Bandeira et al. 1990).  
Probiotic bacteria are of particular importance in modulating the mucosal immune system 
of the gut.  These tissues are collectively known as the gut-associated lymphoid tissues 
and primarily consist of the mesenteric lymph node, Peyer’s patches, and hematopoietic-
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derived cells such as lymphocytes, dendritic cells, and isolated lymphoid follicles, which 
are the primary location of intestinal B cells (Caballero-Franco et al. 2007).  Studies have 
revealed that colonization of the gut leads to increased numbers of intraepithelial 
lymphocytes, antibody-producing cells, and antibody concentration in sera (Hakansson 
and Molin 2011).  The lamina propria secretes IgA (sIgA) that is luminal bacteria-
specific in CV mice; however, sIgA is not present in the GIT of GF mice, suggesting that 
the gut microbiota stimulate the production and secretion of intestinal IgA.  The sIgA 
protects the host against the luminal microbiota that penetrates the epithelial barrier 
(Macpherson and Harris 2004).  Furthermore, Bacteroides thetaiotaomicron-colonized 
gnotobiotic mice implanted with hybridoma cells producing B. thetaiotaomicron-specific 
IgA had a decrease in cecal antigen (Peterson et al. 2007).  These results suggests that the 
commensal gut microbiota and probiotic bacteria influence the intestinal immune system 
and specific host immune tolerance of the commensal microbiota.   
 There are three postulated mechanisms for probiotic modulation of the innate 
immune system: (i) functional regulation of intestinal epithelial cells through direct 
contact, (ii) probiotic bacteria transported through micro-fold (M) cells activate 
phagocytic cells within the Peyer’s patches, and (iii) dendritic cells (DC) in the lamina 
propria recognize probiotic bacteria through pattern recognition receptors (PRR), such as 
Toll-like receptors (TLR) (Hardy et al. 2013). 
 Many probiotic bacteria adhere and interact directly with intestinal epithelial 
cells, and it is believed that this is the mechanism they exert to modulate host immunity.  
A mixture of probiotic bacteria, VSL#3, increased the production and secretion of mucin 
in vitro in both human colon epithelial cells (LS 174T) and rat colonic loops (Caballero-
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Franco et al. 2007).  Probiotic and commensal bacteria have the ability to influence the 
inflammatory signaling pathway through direct contact with intestinal epithelial cells.  
The nuclear factor kappa B (NF-?B is the prominent inflammatory signaling pathway.  
Under anti-inflammatory (non-stimulatory) conditions, the cytoplasmic NF-?B is bound 
to an inhibitor molecule, which renders it inactive; however, when inflammation is 
stimulated, the inhibitor molecule is phosphorylated, making NF-?B active and 
subsequently activates transcription of proinflammatory genes in the nucleus.  Several 
studies have revealed that probiotic strains are able to inhibit phosphorylation of the NF-
?B inhibitor and thereby negate inflammation.  Interestingly, this also inhibits the 
secretion of IL-8, a proinflammatory cytokine, by intestinal epithelial cells, which further 
negates intestinal inflammation (Thomas and Versalovic 2010). 
Probiotic bacteria taken up by M cells have the potential to activate phagocytic cells 
(macrophages, monocytes, and neutrophils) and natural killer cells (NK), as well as 
dendritic cells.  In this way, probiotic as well as commensal bacteria have the ability to 
“tune” the innate immune system, which enables its rapid response to enteric pathogens.  
This ability to “tune” or prime the immune system is demonstrated by the ability of 
probiotic bacteria to elicit pro-IL-1? production by intestinal macrophages; thus allowing 
for rapid conversion to active IL-1? (Franchi et al. 2012).  This can lead to a variety of 
cytokine expression and subsequent activation of immune cells.  Two key cytokines 
dictate the direction of an immune response, IL-10 and IL-12.  IL-12 is involved in 
activation of cellular immunity and cytotoxic cell function, whereas IL-10 suppresses IL-
12 function and reduces inflammation leading to a reduction in immune response (Shida 
et al. 2006).  Konieczna et al.(Konieczna et al. 2012) determined that Bifidobacterium 
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spp. can induce high levels of IL-10 production in human DCs, whereas Lactobacillus 
cannot.  The activation of IL-10 is a key factor in priming the host immune system, while 
negating a negatively inflammatory state.  In a human study in which elderly participants 
were supplemented with L. rhamnosus, results revealed that the probiotic-supplemented 
group experienced an increase in peripheral blood NK cell counts compared to the 
control (Gill and Rutherfurd 2001b; a).  In vitro studies have revealed that probiotic 
bacteria induce IL-12 activity in macrophages, subsequently stimulating NK activity 
(Dong et al. 2010), which could be an insight into the mechanism by which certain strains 
of Lactobacillus spp. potentially activate NK cells.  Not only do probiotic bacteria 
increase the number of peripheral blood lymphocytes, but they also enhance their 
phagocytic capacity (Gill 2003). In vitro studies in RAW264.7 macrophages exposed to 
cell wall extracts of B. adolescentis BBMN23, B. longum BBMN68, and L. salivarius 
Ren revealed enhanced phagocytic activity via increased production of IL-6 and TNF-? 
(Yuanmin et al. 2011).  Similarly, Kaushal and Kansal (Deepti and Vinod 2014) 
determined that mice orally administered with L. acidophilus and B. bifidum had an 
increased production of reactive oxygen intermediates and enhanced phagocytic activity 
in macrophages.  Many of the immune functions that are carried out by immune cells are 
mediated by cytokines.  Administration of probiotic bacteria has a major effect on 
modulating cytokines.  For example, specific strains of probiotic bacteria have increased 
the expression of INF-?, IFN-?, and IL-12 (Arunachalam et al. 2000).  Similarly, long-
term consumption of probiotic bacteria in yogurt increased production of IL-1, IL-1?, IL-
6, IL-10, IL-12, IL-18, INF-?, and TNF-? by monocytes and DC (Cross 2002; Gill and 
Guarner 2004; Niers et al. 2005).   
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Probiotic and pathogenic bacteria have conserved extracellular features that interact 
with host immune cell PRR like their interaction with epithelial cells, discussed 
previously.  For example, the flagellin expressed by some probiotic bacteria for 
chemotaxis and cellular adhesion also interacts with dendritic cells sequestered in the 
lamina propria and stimulates production of cytokines which are responsible for initial 
immune responses, chemokine production and antimicrobial peptide secretions 
(Kinnebrew et al. 2012). Probiotic bacteria have a potent ability to stimulate innate 
immunity, which plays a role in the stimulation of adaptive immune modulation.  
Probiotic bacteria have an “adjuvant” effect, meaning they possess the ability to stimulate 
a humoral immune response (Hall et al. 2008; Belkaid and Hand 2014).  For example, 
antigen-presenting dendritic cells stimulate a T-cell response. Several studies have 
revealed that L. rhamnosus can regulate Th1/Th17 cells by an increased pro- Th1/Th17 
cytokine release by DC (Lin et al. 2009; Yu et al. 2010).  B-cell-secreting IgA is an 
important part of humoral mucosal immunity.  Orally administered L. gasseri increased 
intestinal IgA secretion and induced TGF-? production in DC (Sakai et al. 2014).  There 
have been several animal and clinical studies conducted in an attempt to elucidate the 
immunomodulatory effects of probiotic bacteria.  Together, they present a multifaceted 
and very complex network of cooperation among probiotic bacteria, epithelial cells, 
GALT, and immune cells.   
  
2.9.3.? Enhancement of intestinal barrier function by probiotic bacteria 
The physical barriers that separate self from non-self are the first line of defense 
in the innate immune system. With respect to enteric pathogens, this is the epithelial 
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barrier of the GIT.  This intestinal epithelial barrier has mechanisms that enhance barrier 
function such as mucus secretion, chloride and water secretion, and cellular junction 
maintenance (Thomas and Ockhuizen 2012).  Loss of barrier function is commonly 
referred to as “leaky gut.”  It is well-established that disruption of intestinal barrier 
function can lead to inflammatory bowel disease (IBD), several diarrheal diseases, enteric 
infection, and other autoimmune diseases (Xavier and Podolsky 2007).  Probiotic bacteria 
can prevent or improve leaky gut resulting from food antigens, enteric pathogens, 
proinflammatory cytokines, and immune dysregulation (O'Hara and Shanahan 2007).   
 The epithelial barrier is covered by a protective layer of mucus largely produced 
by goblet cells throughout the GIT.  The proportion of goblet cells to epithelial cells is 4-
16% depending on the location within the GIT.  Goblet cell occurrence and mucus 
thickness is least in the duodenum, increasing in occurrence and thickness through the 
small intestine until the descending colon (Goto and Kiyono 2012).  Several probiotic and 
commensal bacteria are able to influence goblet cell number and mucus production (Ng 
et al. 2013; Tomas et al. 2013; Pelaseyed et al. 2014).  To translocate across the epithelial 
barrier, pathogenic bacteria must first penetrate the protective gel layer of proteolytic-
resistant mucin.  Many bacteria have developed mechanisms to degrade the mucin to 
uptake nutrients or gain access to the epithelial cells underneath (Ohland and 
MacNaughton 2010).  Intestinal inflammation plays an important role in pathogen 
invasion of mucus layer because under inflammatory conditions the mucus layer becomes 
thin, granting access to potential pathogens that would otherwise not have been able to 
penetrate the mucoid layer (Ng et al., 2013).  While it is well-established that several 
probiotic strains of Lactobacillus and VSL#3 can stimulate mucus production (Mack et 
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al. 2003; Caballero-Franco et al. 2007), the mechanism of action has been elusive.  
However, in a recent study using Ruminococcus gnavus E1 revealed there was an 
increased expression of the mucin-encoding genes MUC1, MUC 2 and MUC3 which 
resulted in increased glycosylation by goblet cells that correlated with an increase in 
mucin production (Graziani et al. 2016). 
 The integrity of the epithelial barrier is largely due to cell to cell junction 
complexes.  These complexes consist of the tight junctions, adherent junctions, gap 
junctions and desmosomes.  The tight junction is comprised of some 50 proteins that 
consist of transmembrane proteins that are anchored to the actin cytoskeleton.  
Regulation of these proteins are paramount to the integrity of the junction, and 
subsequently the epithelial barrier.  Several enteric pathogens have evolved mechanisms 
to circumvent and cross the epithelial barrier via both intracellular and paracellular means 
(Guttman and Finlay 2009; Goto and Kiyono 2012).  Similar to the thinning of the mucus 
layer, chronic inflammation plays a role in barrier function and promotes pathogen 
permeation of the barrier.  In in vitro and in vivo studies, L. plantarum restored tight 
junction protein integrity after disruption with unconjugated bilirubin administration 
(Zhou et al. 2010).  Similarly, pretreatment with L. acidophilus or S. thermophilus both 
decreased permeability in vitro and in vivo (Ahrne and Hagslatt 2011).  
 
2.10.?Probiotic control of enteric pathogens 
There has been substantial research into the use of probiotic bacteria to control 
enteric pathogens over the past five decades.  The scope of the research has narrowed 
from understanding which probiotic strains or mixtures could positively enhance the 
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resistance of humans or feed animals to pathogenic bacterial infections to bioengineering 
designer probiotic bacteria that elicit specific protective qualities against specific 
pathogens.  There is great potential for these bioengineered probiotics to provide 2-fold 
protection, including (i) a bioengineered defensive function, and (ii) conferring the native 
health benefits previously discussed in this chapter such as enhanced intestinal barrier 
function and production of antimicrobial compounds.  Several studies have revealed the 
efficacy of wild-type and recombinant, bioengineered probiotics in suppressing enteric 
pathogen infection (Salminen et al. 2010; Bhunia 2012; Dobson et al. 2012; Fijan 2014).  
This next section addresses probiotic-based mediation of enteric pathogens. 
 
2.10.1.?  Probiotic control of foodborne pathogens 
Over the last few decades, our understanding of the relationship between the diet 
and general health has evolved from the simplistic perception of primarily only an 
acquisition of nutrients needed for metabolism to a greater understanding of how specific 
foods promote the overall well-being of an individual (e.g., “superfoods,” antioxidants, 
anti-inflammatories, etc.).  This understanding fostered the use of the term “functional 
foods.”  Foods that, beyond simply providing nutritional value, can benefit additional 
specific functions within the body, are considered functional foods (Figueroa-Gonzalez et 
al. 2011).  Because of their ability to specifically enhance gut health and function, 
probiotics may be considered to be a functional food (Nagpal et al. 2012).  Probiotics are 
typically nonpathogenic microorganisms that promote health benefits when administered 
in clinically-appropriate dosing.  The most common probiotics are Lactobacillus and 
Bifidobacterium.  To be considered a probiotic, a microorganism must exert benefits in 
  
41  
three ways: (i) Provide the host with organic acids (short chain fatty acids) through 
anaerobic fermentation of carbohydrates that can be positively utilized by the host.  There 
has been a wealth of recent studies investigating the wide reach of these fermentation 
endproducts, suggesting that they play a major role in brain function and cognition. (ii) 
Stimulate or prime the host immune system, without causing inflammation within the 
gastrointestinal tract (GIT).  (iii)  Exclude pathogens in the GIT from causing disease by 
outcompeting them for the limited resources and space (Stecher and Hardt 2011). In 
general, probiotics are known to prevent/alleviate chronic inflammatory bowel disease, 
colorectal cancer, metabolic disorders, allergic response, obesity, and osteoporosis 
(Azcarate-Peril et al. 2011; Ly et al. 2011; Amalaradjou and Bhunia 2012; Cate et al. 
2015; Kim et al. 2016). They are also administered in preterm neonates to allow early 
colonization of beneficial microorganisms (Deshpande et al. 2011)   
Further, probiotics must be administered in adequate amounts to be beneficial.  
Widespread colonization of the gut by probiotics can obstruct pathogen access to the 
physical niche required for attachment and infection (Gaggia et al. 2010).  If physical 
displacement is insufficient and a pathogen is able to colonize, probiotics have several 
functional attributes which allow them to effectively subvert pathogen infections within 
the gut.  Like many microorganisms trying to survive within a complex ecosystem, 
several probiotics can inactivate pathogens through the secretion of antimicrobial 
peptides, called bacteriocins (Klaenhammer 1993; Amalaradjou and Bhunia 2012).  As 
previously stated, probiotics stimulate the host immune system, allowing for a prompt 




2.10.2.?  Salmonella 
Salmonella is a predominant cause of human foodborne disorders worldwide and 
is associated with a wide variety of food, including raw poultry and eggs, fish, and fruits 
and vegetables, nuts, dry milk, infant formula, spices, etc.(Carrasco et al. 2012) .  It is a 
zoonotic pathogen with a natural reservoir in livestock, especially chickens, which, when 
consumed, transfers the live pathogen to the GI tract of the host (Foley and Lynne 2008; 
Das et al. 2013).  Multiple strategies have been employed to address exclusion of this 
pathogen from food production and subsequently the food supply (Vandeplas et al. 2010).  
Several studies have revealed that administration of probiotic microbes directly to broiler 
chickens may reduce Salmonella contamination, thus reducing human exposure through 
contaminated food (Van Coillie et al. 2007; Higgins et al. 2008).  Higgins et al. (Higgins 
et al. 2008) determined that challenging neonatal broiler chicks with Salmonella 
Enteritidis and subsequently feeding them increasing doses of Lactobacillus, resulted in 
up to an 85% reduction in the prevalence of Salmonella. Another study revealed that L. 
rhamnosus reduced epithelial cell stress due to S. Typhimurium adhesion and invasion in 
vivo (Burkholder and Bhunia 2009). Not only did administration of L. plantarum improve 
the growth performance of pigs, but it also reduced fecal shedding of S. Typhimurium 
(Gebru et al. 2010).  Oral administration of lactic acid bacteria to broiler chickens not 
only reduced the transmission of S. Typhimurium from the GI tract to the spleen and 
liver, but also down-regulated SPI-1 virulence gene expression, which is necessary for 
intracellular multiplication (Xiaojian et al. 2014).  Interestingly, in an in vitro study using 
an intestinal fermentation system with immobilized fecal microbiota, Bifidobacterium 
thermophiles RBL67 inhibited S. Typhimurium when administered either pre- or post-
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challenge (Tanner et al. 2016).   In contrast, hens and broiler chickens receiving a 
combination of probiotics that included Bacillus subtilis, Lactobacillus acidophilus, L. 
casei, Enterococcus faecium, and Bifidobacterium longum in their feed had no significant 
reduction in the carriage of S. Enteritidis (Murate et al. 2015).  This difference in results 
highlights the strain-specific attributes of probiotic bacteria and their interactions with 
pathogenic bacteria, host cells, and host microbiota, which is further supported by a meta-
analysis study of competitive exclusion of Salmonella in broiler chickens conducted by 
the Public Health Agency of Canada and the University of Guelph in 2013 (Kerr et al. 
2013). These investigators concluded that of the 214 probiotic trials considered, the 
reduction in prevalence or amount of Salmonella varied considerably (Kerr et al. 2013).  
Lactococcus lactis IL1403 has been engineered to secrete the antimicrobial peptides 
(AMP) Alyteserin-1a and A3APO, both of which are effective against Gram-negative 
bacteria, but not Gram-positive bacteria.  When AMP-expressing L. lactis is co-cultured 
with S. Typhimurium or S. Infantis, the growth of both serovars was significantly 
inhibited compared to the control (Volzing et al. 2013).   
 Because the high health and economic burden of Salmonella, considerable effort 
has been directed toward determining the underlying mechanism of antimicrobial and 
protective effects of probiotic bacteria against Salmonella.  Asahara et al. (Asahara et al. 
2011) identified a correlation between an increase in intestinal organic acids which 
reduced the luminal pH and the inhibition of S. Typhimurium growth in mice 
administered L. casei Shirota. Inhibition of Salmonella growth due to lowered pH has 
been shown in many studies (Fayol-Messaoudi et al. 2005; Asahara et al. 2011; Dobson 
et al. 2012). 
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 Immunomodulation of the innate and adaptive immune system by probiotic 
bacteria correlates with the reduction of Salmonella intestinal and tissue counts in in vivo 
mouse studies.  L. casei CRL administration reduced inflammation, increased bacterial 
clearance due to activated phagocyte activity, increased IgA+-producing cells, and 
increased the intestinal? secretion of pathogen-specific sIgA (de LeBlanc et al. 2010).  
Hence, it appears that the mechanism of reducing pathogen levels in hosts by probiotic 
bacteria is multifaceted and involves reducing the luminal pH by increased organic acid 
concentrations, the production of bacteriocins and modulating the innate and adaptive 
immune systems (Dobson et al. 2012). Although probiotic bacteria have antimicrobial 
activity against Salmonella in an animal’s intestinal tract, these bacteria can also enhance 
the growth performance of these food animals. 
 
 
2.10.3.?  Campylobacter 
Campylobacter jejuni is predominantly a poultry pathogen which colonizes the 
ileum and colon of the GI tract and causes gastroenteritis in humans, characterized by 
fever, abdominal cramps, and diarrhea (Young et al. 2007; Dasti et al. 2010).  
Pathogenesis is well-defined and can be attributed to disruption of the mucosal epithelial 
barrier that occurs during campylobacter adhesion and invasion in the GIT (Boehm et al. 
2011).  Several studies both in vitro and in vivo have revealed that Lactobacillus spp. and 
Bifidobacterium spp. can reduce C. jejuni adhesion to and invasion of cells (Schachtsiek 
et al. 2004; Wine et al. 2009; Neal-McKinney et al. 2012; Tareb et al. 2013).  A recent 
study revealed that reducing C. jejuni adhesion by the probiotic L. gasseri SBT 2055 
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(LG) was due to co-aggregation of the probiotic bacteria and C. jejuni by an interaction 
between the proteinaceous cell surface of LG and C. jejuni.  When protease K-treated LG 
cells were used in in vitro studies, co-aggregation was reduced and adhesion and invasion 
of Int-407 cells were increased compared to Int-407 cells not with treated probiotic 
bacteria, suggesting that surface proteins of L. gasseri play a significant role in reducing 
the adhesion and invasion of C. jejuni (Nishiyama et al. 2014).  Similarly, L. helveticus 
R0052, which efficiently adheres to epithelial cells, was able to competitively exclude C. 
jejuni, resulting in a 55% reduction in invasion into Int-407 cells (Wine et al. 2009).  
Wagner et al. (Wagner et al. 2009) through in vivo studies using defined human 
microbiota-associated Balb/C mice dosed with lactobacilli and bifidobacteria after being 
orally infected with either Salmonella or C. jejuni, determined that the probiotic bacteria 
could successfully colonize the gut and competitively exclude both pathogens.  Enhanced 
colonization resistance against both pathogens was observed.  A Bacillus subtilis 
probiotic isolated having increased motility and an increased ability to occupy sites of 
Campylobacter adhesion within the GIT, provided enhanced protection against 
Campylobacter infection when administered orally to chickens (Aguiar et al. 2013). 
 
2.10.4.?  Shiga Toxin-producing Escherichia coli (STEC) 
STEC are becoming an increased concern as traditionally non-Shiga toxin (STX)-
producing E. coli are discovered to produce Shiga toxin (one or both of the STX proteins, 
STX1 and STX2).  In 2011, in Germany, an outbreak caused by an STX-producing 
enteroaggerative E. coli (EaggEC), typically STX negative, hospitalized 3842 people, 
with hundreds developing hemolytic uremic syndrome (HUS). Interestingly 88 percent of 
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those cases were healthy adults (Beutin and Martin 2012; Muniesa et al. 2012).  This 
would suggest that STEC are capable of causing systemic infection in not only 
immunocompromised individuals but also in healthy people.  STEC are responsible for 
sporadic cases and outbreaks characterized by hemorrhagic colitis, largely resulting from 
ingestion of meat and fruits and vegetables contaminated by STEC containing fecal 
matter.  HUS is the more severe form of STEC infections, occurring in 5-15% of cases 
(Davis et al. 2013).  When the pathogen enters the intestine it begins the synthesis of 
STX, which crosses the epithelial barrier, gains entry into the blood stream, and 
eventually invades and damages kidney cells. The key receptor for STX is 
globotriaosylceramide (Gb3), whereas globotetraosylceramide (Gb4) is the receptor 
associated with the STX variant responsible for the disease in swine (Degrandis et al. 
1989).  Knowledge of the host cell receptor responsible for pathogen attachment can be 
exploited to develop strategies for conferring resistance to the pathogen.  In a recent 
study, recombinant probiotic E. coli R1 expressing globotetraose, which mimics an STX 
receptor on its surface, were twice daily administered to piglets 24 hours after receiving a 
dose of STEC. The recombinant E. coli significantly reduced fecal toxin excretion by day 
3; however, despite the reduction of intestinal toxin, the probiotic was not successful in 
reducing the frequency of vascular lesions and clinical disease (Hostetter et al. 2014).  
Many other studies with probiotic bacteria in mice have shown efficacy in reducing or 
preventing disease when wild-type probiotics, especially Lactobacillus, are administered 
prior to infection with STEC (Tsai et al. 2010; Eaton et al. 2011).  In contrast, it appears 
the globotetraose expressing probiotic bacteria were effective in neutralizing STX, but 
not attenuating disease.  As described above in the section on Salmonella, L. lactis has 
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been engineered to secrete anti-Gram-negative bacterial AMP.  The recombinant L. 
lactis-secreting alyteserin-1a inhibited the growth of E. coli O157:H7 when co-cultured 
(Volzing et al. 2013).  With additional studies, this recombinant probiotic bacterium may 
provide useful for suppressing STEC in both human and animal systems. 
 
2.10.5.?Listeria monocytogenes 
Listeria monocytogenes is a rare enteric pathogen because it is generally not 
associated with gastric distress, rather it causes a severe invasive systemic infection in 
high-risk individuals such as pregnant women, newborns, the elderly, and the 
immunocompromised (Swaminathan and Gerner-Smidt 2007).  While L. monocytogenes 
is associated with a relatively low morbidity when compared to other enteric pathogens 
such as Salmonella, the mortality rate is very high (20-30%) (Voetsch et al. 2007).  Kirk 
et al (Kirk et al. 2015) estimated that there were 14,169 cases of L. monocytogenes 
infections leading to 3,175 deaths globally in 2010.  This equates to a staggering 22.4% 
mortality rate.  L. monocytogenes, after surviving the gastric juices of the stomach and 
arriving at the intestinal tract, attaches to and invades epithelial cells both intracellularly 
and paracellularly, and disseminates to the mesenteric lymph nodes (MLN), liver, spleen, 
and can eventually penetrate both the blood-brain and blood-placental barriers 
(Burkholder et al. 2009; Ribet and Cossart 2015).  After penetrating the blood-placental 
barrier, L. monocytogenes can induce microabscesses and necrosis, resulting in preterm 
spontaneous abortion, stillbirth, and miscarriage (Vazquez-Boland et al. 2001; Bakardjiev 
et al. 2006; Jiao et al. 2011).  Several studies investigating the feasibility of probiotic 
intervention of listerial infection have been performed.  L. casei Shirota-fed rats not only 
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had a reduced L. monocytogenes load in the GIT, spleen, liver, and feces, but also had a 
delayed hypersensitivity to the pathogen suggesting an increased cell-mediated immune 
response (de Waard et al. 2002). Similarly, L. delbrueckii provided a protective effect 
against colonization, advanced clearance of L. monocytogenes, and an increase in IFN-? 
and IL-10 (dos Santos et al. 2011).  This study highlights the role of host immune 
modulation in probiotic-induced protection against and clearance of Listeria.  
Additionally, L. plantarum can reduce the production of proinflammatory cytokines 
necessary for Listeria-mediated cytotoxic effect (Puertollano et al. 2008).  Bacteriocin 
production by probiotic bacteria can directly inhibit pathogens.  L. salivarius produces a 
bacteriocin that provides protection against listerial infection (Corr et al. 2007). In 
contrast, Lactococcus lactis, which produces lacticin, provides strong protection in vitro, 
but failed to protect against Listeria infection in in vivo mouse and pig studies (Rea et al. 
2007; Dobson et al. 2011; Rea et al. 2011).  Similarly, in a recent study, Fernandez et al. 
(Fernandez et al. 2015) determined that a pediocin producer, Pediococcus acidilactici 
UL5 was able to affect the metabolic activity (increased production of acetic and 
propionic acids) of immobilized intestinal microbiota in a bioreactor, but it was unable to 
inhibit L. monocytogenes growth within the reactor.  These studies highlight the species 
and stain specificity of the antimicrobial action of probiotic bacteria and the potential 
lack of relationship between in vitro and in vivo study results.  A recombinant L. 
paracasei strain expressing Listeria adhesion protein (Burkholder and Bhunia 2010; 
Jagadeesan et al. 2010) developed by Koo et al. (Koo et al. 2012) had reduced L. 
monocytogenes adhesion, invasion and translocation in Caco-2 cell culture model.  The 
recombinant probiotic bacterium expresses LAP, an essential virulence factor that aids in 
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adhesion to and paracellular translocation of L. monocytogenes across intestinal epithelial 
cells that are anchored to the cell wall.  LAP interacts with the host Hsp60 (receptor) and 
facilitates L. monocytogenes extraintestinal dissemination across the epithelial barrier 
(Burkholder and Bhunia 2013; Kim and Bhunia 2013).  LAP not only enhances probiotic 
bacteria binding to the host GIT and attached to a L. monocytogenes receptor, but also 
may allow the probiotic bacteria to be administered frequently to the host for enhanced 
binding of the probiotic bacteria. 
 
2.10.6.?Viral pathogens 
Norovirus (NoV) is the leading cause of foodborne and waterborne acute 
gastroenteritis worldwide (Jianrong et al. 2012; Rodriguez-Lazaro et al. 2012; Rubio-del-
Campo et al. 2014). In the United States, it is responsible for an estimated 23 million 
cases of gastroenteritis and 50,000 hospitalizations each year (Patel et al. 2009; Mattison 
2011).  The resulting symptoms of a NoV infection continue for 12-60 h and include 
gastroenteritis, self-limiting diarrhea, vomiting, and, in some cases, dehydration and 
death (Rubio-del-Campo et al. 2014).  Recently, a recombinant probiotic Lactobacillus 
paracasei (rLbp) secreting 3D8 single-chain variable fragment (3D8 scFv), an antinucleic 
acid antibody which can penetrate a cell and hydrolyze DNA, has antiviral activity in 
both in vitro RAW 264.7 cell culture models and in vivo mouse models (accepted model 
for NoV) (Phuong Mai et al. 2015).  Mice pretreated with rLbp secreting 3D8 scFv (3 
administrations orally over 6 days) had a 20-fold reduction in mRNA expression of the 
viral polymerase gene compared to mice pretreated with the empty vector rLbp; however, 
no change in viral-associated cytokine levels were observed.  This could be the result of 
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the small number of oral administration of probiotic bacteria (Phuong Mai et al. 2015).  
In a human study, fermented milk containing L. casei Shirota was given to patients 
suffering from NoV infection.  The treatment group had a decreased duration of fever and 










CHAPTER 3. RECOMBINANT LISTERIA ADHESION PROTEIN EXPRESSING 





Ubiquitous, opportunistic foodborne pathogen, Listeria monocytogenes is 
responsible for listeriosis, a systemic infection in immunocompromised individuals and 
premature birth, stillbirth, or abortion in pregnant women.  To cause this severe systemic 
infection and infect the fetuses of pregnant individuals, L. monocytogenes must survive 
the harsh environment of the stomach and breach the intestinal epithelial barrier and host 
innate defense to gain entry into the blood stream and access to successive organs and 
tissues.  L. monocytogenes has become a proficient human pathogen through expression 
of a variety of virulence factors allowing it to evade host immune system, translocate 
across barriers, and spread cell-to-cell (Marco et al. 1997; Hamon et al. 2006; Sleator et 
al. 2009).  Two well characterized mechanisms that L. monocytogenes employs to invade 
and cross the gut barrier are, passive invasion through microfold (M) cells (Pron et al. 
1998) and active invasion via virulence factor Internalin A (InlA) (Lecuit et al. 1999; 
Lecuit et al. 2000; Lecuit et al. 2001).  Bacterial InlA interacts host receptor E-cadherin 
located on the basolateral side of the adherens junction (AJ), which is inaccessible to 
luminal L. monocytogenes (Pizarro-Cerdá et al. 2012); however, there have been 
proposed mechanisms suggesting that the InlA/E-cadherin interaction is possible during 
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epithelial cell extrusion (Pentecost et al. 2006) or mucus exocytosis from goblet cells 
(Nikitas et al. 2011). 
 InlA interaction with E-cadherin is highly host species specific and a single amino 
acid substitution of Glu for Pro inhibits the interaction in mice and rats, as opposed to 
humans (Lecuit et al. 1999); however, L. monocytogenes  has been shown to cross the 
intestinal epithelial barrier in these non-permisive species, suggesting that other 
translocative mechanisms occur (Burkholder and Bhunia 2010; Ghanem et al. 2012).  Our 
lab has demonstrated that the moonlightling protein Listeria adhesion protein (LAP) 
interacts with host moonlighting protein heat shock protein 60 (Hsp60) (Wampler et al. 
2004) to adhere to the host intestinal epithelial cell and invade independent of InlA 
(Burkholder and Bhunia 2010; Drolia et al. 2016).  LAP is a 866 amino acid 
housekeeping alcohol aldehyde dehydrogenase involved in bacterial metabolism 
(Jagadeesan et al. 2010). LAP secretion  is SecA2-dependent and it extracellularly binds 
to bacterial cell wall (Burkholder and Bhunia 2010). Importantly, LAP expressed in 
pathogenic L. monocytogenes shared homology with non-pathogenic LAP expressed in L. 
innocua (Jagadeesan et al. 2010; Jagadeesan et al. 2011).  Hsp60 is a incracellular 
chaparone protein that is also found in the cell membrane of intestinal epithelial cells 
(Wampler et al. 2004). 
 Currently the only mitigation stratagy endorsed by the CDC is, if 
immunocompromised or pregnant avoid high risk foods such as ready-to-eat deli meats, 
hotdogs, dairy products and produce such as cantalopes and apples.  Despite these 
restrictions, L. monocytogenes is still has a mortality rate of 20-30%, making it one of the 
highest mortality foodborne, enteric pathogens (Voetsch et al. 2007).  This suggests that 
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new intervention methods are required.  Pathogen interaction with the intestinal mucosa 
is the first important interaction between pathogen and host (Finlay and Falkow 1997), 
therefore, it would be prudent to investigate mitigation strategies focusing on this 
interaction and subvert further pathogenesis.  Probiotic have recently become an 
attractive option for prophylactic treatment of enteric pathogens because they are able to 
persist in the gastrointestinal tract and hold the possibility of direct or indirect inhibition 
of enteric pathogens.  One of the most common probiotic genera supplemented is 
Lactobacillus, for its ability to colonize and persist in the gut, to enhance host gut 
microbiome, influence the host immune system enhancing gut homeostasis), and to 
enhance host gut barrier integrity (Amalaradjou and Bhunia 2012; Hill et al. 2014; 
Sanders et al. 2014). However, these activities are unpredictable and highly strain 
specific (Hill et al. 2014). 
 To  enhance the efficacy of probiotic therapy and provide a target specific 
mechanism of pathogen inhibition or neutralization, probiotics have been engirnnered to 
express recombinant pathogen specific virulence factors or antimicrobial molecules to 
increase efficacy of specific pathogen mitigation (Chang et al. 2003; Focareta et al. 2006; 
Mohamadzadeh et al. 2010; Amalaradjou and Bhunia 2013).  Following this template, we 
investigated the efficacy of Lactobacillus casei ATCC 334 expressing cell wall anchored 
LAP from either L. monocytogenes (pathogenic) or L. innocua (non-pathogenic).  Here 
we show that these probiotics are able to mitigate L. monocytogenes dissemination to 
extraintestinal tissues, improve gut barrier function, and modulate host immune response 




3.2.  Materials and Method 
3.2.1? Bacterial strains, growth conditions, and inoculum preparation 
  All Listeria species were grown in tryptic soy broth containing 0.6% yeast extract 
(TSBYE; Becton Dickinson, Sparks, MD) or Luria-Bertani broth (LB, 0.5% NaCl, 1% 
tryptone peptone, and 0.5% yeast extract) at 37°C for 16 to 18 h.  Probiotic bacteria were 
cultured in deMan Rogosa Sharpe broth (MRS, Becton Dickinson) at 37°C for 18-20 h. 
Lactobacillus casei ATCC 344 wild type (LbcWT) (a gift from Mike Miller, University 
of Illinois, Urbana) was used as a host to express LAP from L. innocua (LbcLAPLin) and 
L. monocytogenes (LbcLAPLm). To recover this strain from fecal and intestinal samples 
during animal study, a vancomycin resistant strain of L. casei was selected by 
sequentially culturing the bacterium in increasing concentrations of vancomycin (300 
?g/ml). LbcWT was grown under anaerobic conditions at 37°C.  Recombinant L. casei 
strains were grown under anaerobic conditions at 37°C with erythromycin (2 μg/mL).  
 LbcWT, LbcLAPLm, and LbcLAPLin probiotic supplement was prepared by 
growing the probiotics overnight and pelleting them by centrifugation 8000 xg for 10 
min.  The probiotic pellet was washed with sterile water and pelleted again.  The washed 
probiotic pellets were resuspended in 30 ml of sterile water at a concentration of 9 ? 109 
cfu/ml and supplied to animals in the drinking water bottle.  L. monocytogenes challenge 
was prepared by pelleting an overnight grown culture by centrifugation at 8000 ?g for 3 
min.  The pelleted cells were washed in sterile PBS and pelleted again.  Washed pellet 







Table 3-1.  Bacterial strains and culture conditions 
Bacterial 

















- Aerobic 16-18 37oC 
LbcWT MRS, MRSA - Anaerobic 12-14 37
oC 
LbcLAPLm MRS, MRSA 
erythromycin 
(2 μg/ml) Anaerobic 12-14 37
oC 
LbcLAPLin MRS, MRSA 
erythromycin 
(2 μg/ml) Anaerobic 12-14 37
oC 
TSBYE, tryptic soy broth containing 0.6% yeast; TSAYE, tryptic soy agar containing 
0.6% yeast extract; MOX, modified oxford agar; MRS, deMan Rogosa Sharpe broth; 
MRSA, deMan Rogosa Sharpe agar 
 
3.2.2? Mouse bioassay 
 
 Female mice (A/J: 8-10 weeks of age; n=24) were purchased from Jackson 
laboratories (Bar Harbor, Maine). The animal bioassay procedure was approved by the 
Purdue University Animal Care and Use Committee (1201000595A003). Upon arrival, 
mice (1/cage) were housed in cages that included nesting cotton for enrichment. 
Shepherd's™ ALPHA-dri® (alpha cellulose) was used for bedding. Animals were 
provided adlib feed (Rodent Diet 5001, LabDiet, Brentwood, MO) and sterile deionized 
water, and acclimatized for 5 days before the experiment. A cycle of 12 h artificial light 
and 12 h darkness was maintained. Relative humidity was 50-60% and temperature was 





Table 3-2.  Mouse grouping and treatments 
Group number Treatment No. of mice per group 
I No Lbc 6 
II No Lbc + Lm 3 
III LbcWT 3 
IV LbcWT + Lm 3 
V LbcLAPLm 3 
VI LbcLAPLm + Lm 3 
VII LbcLAPLin 3 
VIII LbcLAPLin + Lm 3 
 
Fresh preparations of probiotics were supplied daily through sterile deionized water at 9 
? 109 CFU/ml for 10 days (Fig 3-1).  All mice consumed a minimum of 5 ml of 
probiotics each day.  Control animals received only sterile water. For challenge 
experiment, mice received oral gavage of L. monocytogenes F4244 (WT) at a 
concentration of 8.8 ? 108 CFU/mouse using a feeding tube (Popper) and control mice 
received PBS (Burkholder et al. 2009). Animals were observed for clinical signs of 
infection, such as ruffled hair, movement and recumbence, and their feeding and drinking 
habits. 
 Mice were euthanized by CO2 asphyxiation at 48 h pi, and intestine (duodenum, 
jejunum and ileum), spleen, liver, kidney, lungs and blood from the heart via a cardiac 
puncture were aseptically collected.  Intestinal homogenates were frozen and stored at     
-80oC the same day after enumeration for future cytokine quantification.  Feces were 
collected from each mouse from time of infection to sacrifice.  Organs were homogenized 
using a tissue homogenizer (Cole Parmer, Vernon Hills, IL) in 0.5 ml (blood), 4.5 ml 
(spleen, kidney, lungs) or 9 ml (feces, intestine, liver) of PBS. MRS agar (Neogen, 
Lansing, MI) containing vancomycin (300 ?g/ml) was used for enumeration of LbcWT, 
and MRS agar containing erythromycin (2 ?g/ml) was used for bioengineered strains.  




microcentrifuge tubes (Fisher Scientific, Waltham, MA).  Blood (50 -250 μl/animal) was 
collected by cardiac puncture and stored in individual microcentrifuge tubes and sera was 
obtained (section 3.3.4). Sera and urine were appropriately diluted and assayed for FD4 
by measuring in a spectrophotometer as described (Condette et al. 2014).  
 
3.2.5.? Cytokine quantification by ELISA 
 
Caco-2 monolayers (about 12 days of incubation) were grown in 12 well plates in 
Hyclone High Glucose Dulbecco’s modified Eagle medium (DMEM) (GE) containing 
10% fetal calf serum (GE).  Probiotics were grown in MRS or MRS containing 
erythromycin (2 μg/mL) for 12 h anaerobically at 37oC statically.  Probiotic cultures were 
pelleted by centrifugation at 8,000 xg for 5 min and washed with sterile PBS.  Probiotics 
were suspended in serum free Hyclone High Glucose DMEM (GE), introduced to the 
monolayer at an MOE of 10:1 and incubated for 24 h.  Non-adherent probiotics were 
washed off the monolayers with buffered PBS.  L. monocytogenes for challenge was 
grown in TSBYE for 16 h and a 1% subculturein TSBYE was grown for 6 h to reach the 
appropriate cell density of 108 cfu/ml.  L. monocytogenes was pelleted by centrifugation 
at 8,000 xg for 3 min, washed in 1 ml of sterile PBS, and resuspended in serum free 
DMEM.  The monolayers were challenged with L. monocytogenes at an MOE 10:1 or 
LPS-free purified rLAP (1 mg/ml) for 1 h (See section 3.2.7).  Culture supernatants were 
collected and tested for IL-6 and TNF-? content using sandwich ELISA kits (Raybiotech 
ELH-IL6 and ELH-TNF-?).  Briefly, supernatants were applied to the manufacturer 
supplied pre-coated 96 well ELISA plates (100 ?l/well) and  incubated overnight (16 h).  
Primary biotinylated antibodies specific to IL-6 or TNF-? and streptavidin conjugated 
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secondary antibodies were incubated for 1 h and 45 min, respectively, at room 
temperature. Color was developed as instructed by the manufacturer (Raybiotech) using 
TMB (100 ?l/well) incubated for 30 min at room temperature.  Color development was 
stopped by adding stopping solution (50 ?l/well), supplied in the kit.  Color was 
measured at wavelength 450 nm by an Epoch Microplate Reader (Biotek, Winooski, VT). 
Mouse intestinal tissue homogenates were obtained from the mouse bioassay 
samples that were frozen and were thawed overnight at 4oC.  They were assayed for IL-6 
and TNF-? quantification using mouse specific sandwich ELISA kits (Cat No. ELM-
TNF-? and ELM-IL6-CL, RayBiotech, Norcross, GA).  Briefly, ileal tissue homogenates 
from each animal were applied to the manufacturer supplied pre-coated 96 well ELISA 
plates (100 ?l/well) and were incubated overnight (16 h) at 4oC.  Primary biotinylated 
antibodies specific to IL-6 or TNF-? and streptavidin conjugated secondary antibodies 
were incubated for 1 h and 45 min, respectively, at room temperature. Color was 
developed as instructed by the manufacturer (Raybiotech) using TMB (100 ?l/well) 
incubated for 30 min at room temperature.  Color development was stopped by adding 
stopping solution (50 ?l/well), supplied in kit.  Color was measured at wavelength 450 
nm using an Epoch Microplate Reader (Biotek, Winooski, VT). 
 
3.2.6.? Cytokine detection by semi-quantitative array 
Pooled sera from each group was used for a semi-quantitative cytokine array (Cat. 
No. AAM-CYT-1, RayBiotech, Norcross, GA).  Immunoblotting was performed as per 
manufacturer instructions, and the reaction intensity was quantified using the NIH ImageJ 
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software.  The data were normalized to array-specific positive controls and then 
expressed as mean fold change. 
 
3.2.7.? Short chain fatty acid quantification 
Fecal pellets (100?mg) were homogenized in 900?μl of water and 1.4?mm ceramic 
beads using a Precellys 24 homogenizer (Bertin Instruments, Rockville, MD). The 
homogenates were labeled with regular aniline (12C6), and external SCFA standard 
solution (10?mg/ml of acetic acid, propionic acid, and butyric acid) was labeled with 
aniline-13C6 using N-(3-Dimethylaminopropyl)-N?-ethylcarbodiimide hydrochloride 
(2?mg per sample). Crotonic acid (final 0.1?mg/ml) was used as an internal standard. The 
labeling mixture was incubated for 2?h, and triethylamine was added to stop the labeling 
reaction. Samples and standard reaction solution were mixed (1:1) and analyzed with an 
Agilent 6460 Triple Quad LC/MS System (Agilent Technologies, Santa Clara, CA). 
 
3.2.8.? Seroconversion of LAP 
Recombinant LAP (rLAP) was purified using Ni affinity chromatography (See 
method in Appendix A) from E. coli BL21 or ClearColi (Lucigen) and separated by SDS-
PAGE (7.5% Acrylamide).  The protein was electrically transferred to hydrophobic 
membrane, Immobilon-P membrane (Millipore, Billerica, MA).  Equal parts of pooled 
sera from each treatment group were used to immunoprobe the membrane for 16 h at 4oC.  
Horseradish peroxidase conjugated anti-mouse secondary antibody (Cat. No. AP308P, 
Sigma) was used.  The presence of anti-LAP antibodies was detected using the  
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chemiluminescence substrate LumiGLO (Cell Signaling Technology, Danvers, MA) with 
a chemiluminescence detection system (Chemidoc XRS, Bio-Rad). Purified rLAP was 
used as control in each blot.   
 
3.2.9.?     Interaction between probiotics and L. monocytogenes and immunomagnetic 
separation of Listeria 
L. monocytogenes F4244, L. innocua F4248, LbcWT, LbcLAPLm, and LbcLAPLin 
were cultured for 16-18 h at 37oC in TSBYE, MRS, or MRS supplemented with 2 μg/ml 
erythromycin broth, respectively (see section 3.2.1). All cultures were pelleted by 
centrifugation at 8000 xg for 3 min and washed with sterile PBS.  All cellular 
concentrations were serially diluted to obtain a cell concentration of 106 cfu/ml.  L. 
monocytogenes or L. innocua were allowed to interact with the individual probiotic 
strains (LbcWT, LbcLAPLm, or LbcLAPLin) at a 1:1 concentration in sterile PBS for 1 h at 
room temperature with constant agitation on Lab Doctor Revolver (MidSci, Valley Park, 
MO). Anti-Listerial magnetic Dynabeads (Cat. No. 71006, Thermofischer Scientific) 
were used to capture and separate L. monocytogenes and L. innocua from unbound 
probiotics.  Briefly, 20 μl/ml of bead slurry was added to the bacterial mixtures and 
allowed to interact for 10 min at room temperature with constant agitation.  Beads were 
magnetically separated and washed with sterile PBS-T (0.1%) 3 times (10 min each 
wash) with constant agitation.  Beads were serially diluted and plated on MOX (Neogen) 







3.3.2? Recombinant Lactobacillus casei expressing non-pathogenic LAP reduced Lm 
infection 
 
Animals (n=30) were sacrificed 48 h post infection (pi).  L. monocytogenes counts 
in the liver, spleen, MLN, kidneys, blood, intestine, and lungs were determined (Fig. 3-4, 
b-h). Generally, depending on the tissues or organs, the LbcWT feeding resulted in a 
meager reduction of L. monocytogenes counts of only 0-1 log cfu/mouse.  Remarkably, 
the recombinant probiotics (LbcLAPLin or LbcLAPLm) supplied mice showed a reduction 
of L. monocytogenes counts by 3.5-5 log (up to 99.999%) 48 h pi in liver and spleen (Fig. 
3-4, b, c). L. monocytogenes was undetectable in blood and the kidney of recombinant 
probiotic-fed mice (Fig. 3-4, f, h). Furthermore, in the recombinant probiotic -fed 
animals, L. monocytogenes was undetectable from liver or spleen from 25-50% of the 
mice while L. monocytogenes was isolated from all LbcWT–fed animals (n=3-6). No 
background Listeria were detected from mice that received only the probiotics or no 
probiotics at all. Collectively, these data demonstrate that recombinant probiotic were 







Short chain fatty acids (SCFAs), especially butyrate, are also known to maintain 
tight junction integrity (Elamin et al. 2013) and regulate inflammation (Maslowski et al. 
2009; Tremaroli and Backhed 2012; Kim et al. 2013). Therefore, we analyzed SCFAs in 
the feces of mice collected on day 0 and day 12 (day of sacrifice) of probiotic feeding. 
Data show that, in general, all three SCFAs (acetate, propionate and butyrate) levels were 
substantially lower in animals that did not receive any probiotics, but were challenged 
with L. monocytogenes (Fig 3-6). In contrast, SCFAs were maintained at constant levels 
in the animals that were fed with either LbcWT or recombinant probiotics with or without 
L. monocytogenes challenge, similar to the control animals that did not receive any 
treatments. These data show that L. monocytogenes alone was able to alter metabolic 
activity of gut microbes resulting in overall reduced levels of SCFA synthesis while the 
probiotics-fed mice had the ability to attenuate such negative effect, thus possibly playing 






To assess the state of systemic immune response, levels of several cytokines in 
the pooled sera from the three animals within each treatment group were analyzed using a 
semi-quantitative immunoblot array). Data show a very high level of IL-6 (interleukin 6) 
and MCP-1 (monocyte chemoattractant protein 1) in the sera in animals that were 
infected with L. monocytogenes without any probiotics; however, probiotics (LbcWT, 
LbcLAPLm, LbcLAPLin) exposure was able to dampen these two cytokine levels in the 
sera of L. monocytogenes infected mice (Fig 3-8). In contrast, the level of G-CSF 
(granulocyte colony stimulating factor) was very high in sera after L. monocytogenes 
challenge, irrespective of the probiotics used. Serum TNF-? level was undetectable 
irrespective of the treatments.  This may be an artifact of the sensitivity of the cytokine 
array; however, as previously stated, intestinal TNF-? levels were reduced in concert 
















pregnant mothers and their fetuses (Kirk et al. 2015). L. monocytogenes also contributes 
to a costly economic burden.  Currently, there are no medically preventative treatments 
for these high-risk individuals and they are subject to avoidance strategies, such as not 
consuming high-risk foods including ready-to-eat deli meats, soft cheeses, etc.  Probiotics 
offer attractive and cost effective platform to deliver preventative relief to these people; 
however, due to the unpredictable and strain-specific nature of probiotic supplementation, 
targeting specific pathogens proves ineffective.  To address these shortcomings, many 
studies have been conducted measuring the efficacy of recombinant probiotics expressing 
a pathogenic virulence factor, antimicrobial agents such as bacteriocins, or host immune 
proteins such as anti-inflammatory IL-10 to offer target specific intervention 
(Amalaradjou and Bhunia 2012; Koo et al. 2012; Volzing et al. 2013).  These target 
specific enhancements to probiotic supplementation complement the health-positive 
benefits that the native probiotic strain confer, such as enhanced barrier function 
(Salminen et al. 2010; Cho et al. 2014), host immune modulation, short chain fatty acid 
production through carbohydrate fermentation (Ng et al. 2009; Ng et al. 2013), increased 
intestinal mucus production (Williams 2010; Shen-Shih and Tzu-Ming 2012), and safety 
(Amalaradjou and Bhunia 2012; Amalaradjou and Bhunia 2013). 
 The probiotic intervention of Listeria has been generally ineffective (Culligan et al. 
2009; Koo et al. 2012), so to address this ineffectiveness we have developed a probiotic 
that expresses  the LAP to prevent L. monocytogenes from breaching the intestinal barrier 
and dissemination to extraintestinal tissues.  We have shown that LAP has significant 
implications regarding L. monocytogenes adhesion and paracellular invasion of intestinal 
epithelial cells (Burkholder et al. 2009).  LAP is a housekeeping enzyme that moonlights 
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as a SecA2 secreted bacterial cell membrane adhesion protein (Burkholder and Bhunia 
2009); however, LAP lacks a leader peptide and must bind to itself via interaction with an 
unknown cell wall molecule.  LAP from pathogenic L. monocytogenes shares 99.9% 
sequence homology (Amalaradjou et al.in preparation) with LAP from non-pathogenic L. 
innocua, yet LAP from L. innocua cannot re-associate with the bacterial cell wall once 
secreted (Jagadeesan et al. 2010).  This inability of L. innocua to translocate through 
paracellular route plays a significant role in the failure of it to cause infection 
(Burkholder and Bhunia 2010; Burkholder and Bhunia 2013).   
 We have asked the questions, can the LAP expressing recombinant probiotics 
prevent listeriosis in Listeria sensitive A/J mice, and if so, due to the sequence homology 
between pathogenic and non-pathogenic LAP, can a non-pathogenic LAP expressing 
probiotic prevent listeriosis as efficiently a pathogenic LAP.  We found that both 
recombinant probiotics, LbcLAPLm and LbcLAPLin were able to protect the mice against 
L. monocytogenes by a factor of up to 5 log, while the LbcWT strain provided a little or 
no protection at all.  Mice supplied with the recombinant probiotics showed no clinical 
signs of listeriosis post infection.  In contrast, the LbcWT supplied and challenged mice 
were hunched, lethargic, unresponsive, and had a 17% reduction in body weight over 48 
h, showing clear clinical signs of infection.  Mice provided with recombinant probiotics 
continued to eat and drink post infection, while mice provided with LbcWT or no 
probiotics and challenged did not eat or drink post infection. 
 Taken together, data presented here suggest three possible mechanisms by which the 
recombinant probiotics subvert pathogen extracellular dissemination and infection:  (i) 
Enhancement of intestinal barrier function, (ii) Enhancement or “priming” of the host 
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immune system to aid in rapid clearance of the pathogen if it can breach the intestinal 
barrier, and (iii) Direct interaction and binding of L. monocytogenes thus inhibiting the 
pathogen interaction with host epithelial cells.   
 Maintenance of the epithelial junction proteins occludin and claudin is integral to 
intestinal barrier function (Pagnini et al. 2010; Zhou et al. 2010).  In this study we 
observed that recombinant probiotic fed mice that were then challenged by L. 
monocytogenes maintained the same gut permeability as unchallenged mice, while the 
LcbWT-fed and Lm challenged mice showed an increase in gut permeability, suggesting 
that the recombinant probiotics helped maintain gut integrity and mitigated L. 
monocytogenes induced gut permeability, and bacterial paracellular translocation.  
Another factor that impacts gut barrier integrity and homeostasis are SCFA (Hamer et al. 
2008).  SCFA, especially butyrate are the primary source of metabolic energy for 
colonocytes and, as such aids in cellular performance (Plöger et al. 2012).  Moreover, 
SCFA can promote resistance to experimentally derived colitis (Cresci et al. 2013; 
Leonel et al. 2013), suggesting its importance in barrier integrity.  Here we found that L. 
monocytogenes reduced colonic SCFA content and interestingly, probiotic-fed groups 
maintained total SCFA content.  We suspect that the change in SCFA content due to L. 
monocytogenes is due to disruption of the gut microbiome; however, further studies ae 
needed to fully elucidate this difference and its impact on microbiome versus probiotic 
supplementation derived SCFA production.  It is important to note that these mice also 
stopped consuming feed pellets, which could also account for the change in SCFA 
content.    
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 Immune modulation by probiotics has been shown to occur through marginal 
stimulation of intestinal TNF and subsequent NF-?B activation resulting in enhanced 
innate immune function without any detrimental inflammatory responses and aiding in 
gut homeostasis (Pagnini et al. 2010; Nagpal et al. 2012; Ng et al. 2013). Previous in 
vitro studies using RAW264.7 macrophages exposed to cell wall extracts of 
Bifidobacterium adolescentis, B. longum, and Lactobacillus salivarius Ren enhanced 
phagocytic activity via increased production of IL-6 and TNF-? (Zhu et al., 2011).  Oral 
gavage of mice with L. acidophilus and B. bifidum showed increased reactive oxygen 
intermediates production and enhanced phagocytic activity in macrophages (Deepti and 
Vinod 2014).  Long-term consumption of certain probiotics has shown to enhance innate 
immunity and production of IL-1, IL-6, IL-10, IL-12, IL-18, INF-?, and TNF-? by 
monocytes and dendritic cells (Cross 2002; Niers et al. 2005).  L. monocytogenes 
challenge induced high levels of intestinal pro-inflammatory TNF-? and IL-6 as well as 
IL-6 in serum, suggesting a systemic infection.  Recombinant probiotic fed groups proved 
to mitigate local TNF-? and IL-6 expression, while LbcWT did not.   
  In our previous report, LAP induced IL-6 and TNF-? production during L. 
monocytogenes infection through activation of NF-?B (Drolia et al. in preparation), but in 
this study, recombinant probiotics expressing LAP were able to dampen L. 
monocytogenes-mediated proinflammatory cytokine production despite moderate 
activation of NF-?B. This suggests, perhaps that recombinant probiotics helped maintain 
epithelial immune homeostasis thus was able to counteract L. monocytogenes mediated 
inflammatory response. During innate immunity, monocytes secrete IL-6 when 
stimulated by pathogen-associated molecular patterns (PAMPS) on specific pathogens 
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that are recognized by pattern recognition receptors (PRR) including toll-like receptors 
(TLRs) similar to LAP-Hsp60 interaction (Drolia et al., in Preparation).  This suggests 
that the recombinant probiotics can modulate innate immune response and subsequent 
inflammation through either direct or indirect manipulation of pro-inflammatory 
cytokines.   
  SCFA are also known to modulate host immune response by inducing IL-10 and 
IFN-? secretion (Kurita-Ochiai et al. 1995) and induction of Treg cell generation 
(Furusawa et al. 2013) resulting in a reduction of inflammation.  We suspect that the 
maintenance of SCFA in intestinal content contributes to the probiotic modulation of the 
innate immune system.   
  Probiotics have been shown to enhance the mucosal intestinal immune system.  
Gut microbiota have been shown to interact with gut-associated lymphoid tissue (GALT) 
and B cells, and induce secretion of antibodies (Peterson et al. 2007)).  This is an 
important part of the maintenance of intestinal homeostasis.  A study in chickens showed 
that probiotic-supplemented chickens and immunized with sheep red blood cells had 
higher specific serum antibody titer than non-probiotic supplemented groups (Haghighi et 
al. 2005).  Similarly, we also found that the recombinant probiotics were possibly able to 
enhance the adaptive immune response by inducing anti-listerial antibodies in serum of 
challenged animals.  Interestingly, we did not see anti-LAP serum antibodies in 
unchallenged animals supplied with recombinant probiotics, suggesting that the 
recombinant probiotics do not translocate across the intestinal barrier and promote B-cell 
secretion of antibodies against the probiotic itself; however, they can play a role in 
systemic immune response to L. monocytogenes infection.  This may enhance adaptive 
  
79  
immune response against L. monocytogenes resulting in faster and more efficient 
clearance of bacteria that do translocate across the intestinal barrier.   
  Typically, direct probiotic inhibition of a pathogen is described by competitive 
exclusion of the pathogen receptor (Amalaradjou and Bhunia 2013). However, it is 
unlikely that the supplemented probiotic can penetrate the established gut microbiota and 
the loosely and tightly adherent mucus layers to interact directly with the host epithelial 
Hsp60 and competitively inhibit L. monocytogenes, rather it appears that the probiotic 
itself may be binding the pathogen. We demonstrated that the recombinant probiotics 
were able to bind L. monocytogenes 2 log more than LbcWT, while they showed no 
increase in the binding of L. innocua.  Likewise, it is established that SCFA, especially 
acetate and propionate can directly inhibit L. monocytogenes growth (Julotok et al. 2009); 
therefore, the enhancement of SCFA content in recombinant probiotic-fed and Lm-
challenged groups could directly inhibit the pathogen.    
  In conclusion, we demonstrated that recombinant LAP expressing probiotics, 
especially the non-pathogenic LAP expressing probiotic were able to reduce translocation 
and dissemination of L. monocytogenes, enhance gut barrier function, and modulate host 
immune response.  We suspect that a combination of probiotic mechanisms working in 
concert including direct binding of the pathogen and enhancement of cell junction 
proteins and inflammation are responsible; however, whether the recombinant probiotics 
are directly affecting these changes or indirectly through maintenance of the host gut 
microbiome has yet to be elucidated. 
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CHAPTER 4.    LISTERIA ADHESION PROTEIN EXPRESSING PROBIOTICS 
REDUCE EXTRAINTESTIAL DISSEMINATION OF LISTERIA 




Listeria monocytogenes is a Gram-positive bacterium, ubiquitous in nature and is 
associated with foodborne illness transmitted by produce, processed meat and dairy 
products.  L. monocytogenes is a rare enteric pathogen because it is generally not 
associated with gastric distress, rather it causes a severe invasive systemic infection in 
high-risk individuals such as pregnant women, newborns, the elderly, and 
immunocompromised individuals (Swaminathan and Gerner-Smidt 2007).  While L. 
monocytogenes is associated with a relatively low morbidity when compared to other 
enteric pathogens such as Salmonella, the mortality rate is very high (20-30%) (Voetsch 
et al. 2007).  Kirk et al (Kirk et al. 2015) estimated that there were 14,169 cases of L. 
monocytogenes infections leading to 3,175 deaths globally in 2010.  This equates to a 
staggering 22.4% mortality rate.   
To cause systemic infection, Listeria monocytogenes must escape the GI tract and 
disseminate to extra intestinal tissues.  L. monocytogenes has multiple mechanism to 
facilitate this, including the well characterized interaction of Lm virulence factor InlA 
and host E-cadherin (Lecuit et al. 1999; Yu et al. 2012) and passive translocation through 
microfold (M) cells overlaying the Peyer’s patch (Lelouard et al. 2012).
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Alternatively, L. monocytogenes secretes the Listeria Adhesion Protein (LAP), a 
bifunctional house-keeping alcohol acetaldehyde dehydrogenase. Our lab has implicated 
LAP in Lm adhesion to epithelial cells via interaction with host epithelial heat shock 
protein 60 (Hsp60) (Wampler et al. 2004), a moonlighting chaperone protein (Henderson 
et al. 2013), positively influencing Internalin-independent paracellular translocation 
(Burkholder and Bhunia 2010; Burkholder and Bhunia 2013).  Non-pathogenic species of 
Listeria also express the LAP protein. LAP from L. monocytogenes F4244 (pathogen) 
and Listeria innocua F4248 (non-pathogen) have near complete homology (99.4%) 
(Jagadeesan et al. 2010).  Regardless of the mechanism, once L. monocytogenes has 
escaped the GI tract it disseminates to the mesenteric lymph nodes (MLN), liver, spleen, 
blood, and can eventually penetrate both the blood-brain and feto-placental barriers 
(Burkholder et al. 2009; Ribet and Cossart 2015).  Prevention of L. monocytogenes 
translocation across the intestinal epithelial barrier would circumvent L. monocytogenes’ 
ability to cause systemic infection.   
Guinea pigs have classically been used as the model for pregnancy related 
pathogenicity because of the similarity in placental structure compared to humans (Leiser 
and Kaufmann 1994; Bakardjiev et al. 2004).  Additionally, the InlA/E-cadherin 
interaction is host species-specific due to a substitution at the amino acid sequence 
position 16 at which Pro is substituted by Glu in the host species' E-cadherin. InlA may 
have low affinity for mouse or rat E-cadherin but interacts strongly with the E-cadherin 
of permissive hosts, such as humans and guinea pigs (Lecuit et al. 1999). Studies using 
transgenic mice expressing “humanized” E-cadherin (Disson et al. 2008) or murinized 
InlA (InlAm) (Wollert et al. 2007; Ghanem et al. 2012) have indicated that L. 
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monocytogenes may use alternate routes to translocate across the gut mucosa.  So, while 
mice have been deemed an acceptable model for non-pregnant L. monocytogenes 
infectious studies, they are unsuitable for pregnancy related studies.    
Probiotics have the ability to colonize the GI tract and positively benefit the host 
in several ways, thus making them an attractive prospect for therapy against enteric 
pathogens.  Because of their ability to specifically enhance gut health and function, 
probiotics may be considered to be a functional food (Nagpal et al. 2012).  Probiotics are 
typically nonpathogenic microorganisms that promote health benefits when administered 
in clinically appropriate dosing.  The most common probiotics are Lactobacillus and 
Bifidobacterium.  To be considered a probiotic, a microorganism must exert benefits in 
three ways: (i) Provide the host with organic acids (short chain fatty acids) through 
anaerobic fermentation of carbohydrates that can be positively utilized by the host.  There 
has been a wealth of recent studies investigating the wide reach of these fermentation 
products, suggesting that they play a major role in brain function and cognition. (ii) 
Stimulate or prime the host immune system, without causing inflammation within the 
gastrointestinal tract (GIT).  (iii)  Exclude pathogens in the GIT from causing disease by 
outcompeting them for the limited resources and space (Stecher and Hardt 2011). In 
general, probiotics are known to prevent/alleviate chronic inflammatory bowel disease, 
colorectal cancer, metabolic disorders, allergic response, obesity, and osteoporosis 
(Azcarate-Peril et al. 2011; Ly et al. 2011; Amalaradjou and Bhunia 2012; Cate et al. 




One major drawback of probiotics as vaccine is that their protection is 
unpredictable, making it a difficult platform for target specific activity. We have 
bioengineered probiotics expressing the LAP, which enhances the specificity of the 
protection.  Previously our research group has demonstrated that recombinant LAP-
producing probiotics reduce dissemination to extraintestinal tissues 3-5 log in healthy mice, 
suggesting that they are an appropriate protective vaccine against listeriosis. In this study, 
we showed that recombinant probiotics, especially expressing LAP from Listeria innocua 
can reduce dissemination to extraintestinal, placental and fetal tissues in pregnant guinea 
pigs, help maintain intestinal SCFA content, modulate host cytokine expression, and confer 
general health benefits associated with probiotic therapy. 
 
4.2? Materials and Methods 
4.2.1? Bacterial cultures and growth conditions 
 All bacteria used were grown under the same conditions as previously described 
and listed in (Table 4-1) (Amalaradjou et al., in preparation).  The construction of the 
recombinant probiotic strains LbcLAPLm and LbcLAPLin has been previously described 
(Koo et al. 2012).   Briefly, L. monocytogenes F4244 (serovar 4b) was grown in tryptic 
soy broth containing 0.5% yeast extract (TSBYE; Becton Dickinson, Sparks, MD) at 
37°C for 16 to 18 h. Wild type probiotic bacteria were cultured in deMan Rogosa Sharpe 
broth (MRS, Becton Dickinson) or plated on MRS agar and grown at 37°C for 12-14 h.  
Lactobacillus casei ATCC 344 wild type (LbcWT) (a gift from Mike Miller, University 
of Illinois, Urbana) was used as a host to express LAP from L. innocua and L. 
monocytogenes. Recombinant L. casei expressing LAP from L. monocytogenes 
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(LbcLAPLm) and from L. innocua (LbcLAPin) were grown in MRS broth containing 
erythromycin (2 μg/ml) at 37oC for 12-14 h or plated on MRS agar containing 
erythromycin (2 μg/ml).?
Table 4-1.  Bacterial growth requirements 
Bacterial 











- Aerobic 16-18 37oC 
LbcWT MRS, MRSA - Anaerobic 12-14 37
oC 
LbcLAPLm MRS, MRSA 
erythromycin 
(2 μg/ml) Anaerobic 12-14 37
oC 
LbcLAPLin MRS, MRSA 
erythromycin 
(2 μg/ml) Anaerobic 12-14 37
oC 
TSBYE, tryptic soy broth containing 0.6% yeast; TSAYE, tryptic soy agar containing 
0.6% yeast extract; MOX, modified oxford agar; MRS, deMan Rogosa Sharpe broth; 
MRSA, deMan Rogosa Sharpe agar. Recombinant probiotic strains (LbcLAPLm and 
LbcLAPLin) were developed by Amalaradjou et al. (manuscript in preparation). 
 
 
4.2.2? Pregnant guinea pig bioassay 
The animal bioassay procedure was approved by the Purdue University Animal 
Care and Use Committee (1201000595A003). Pregnant Dunkin-Hartley guinea pigs were 
purchased from Elm Hill Labs (Chemsford, MA) on their 24-28th gestational day (Fig 4-
1).  Upon arrival, Guinea pigs (1/cage) were housed in a cage with a hut and chew toy for 
enrichment. Cedar shavings was used for bedding.  Animals were provided adlib feed 
(Guinea Pig Diet 5025, LabDiet, Brentwood, MO) and sterile deionized water, and 
acclimatized for 5 days before the experiment. A cycle of 12 h artificial light and 12 h 
darkness was maintained. Relative humidity was 50-60% and temperature was 20-25°C.?
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Guinea pigs were prescreened for listerial infection.  One day after arrival animal fecal 
pellets were screened for preexisting L. monocytogenes infection by homogenizing 1 g of 
fecal pellets in 10 ml of University of Vermont (UVM, BD) broth and pre-enriched by 
incubating at 37oC for 24 h (pre-enrichment).  One ml of pre-enriched sample was 
enriched for L. monocytogenes in 10 ml of Frasier Broth (BD) at 37oC for 24 h, and 
plated on Modified Oxford (MOX) agar plates.  Any colonies suspected of being L. 
monocytogenes were confirmed by PCR.  Guinea pigs were randomly assigned into five 
groups and experiments were carried out in  two separate trials performed in 2-weeks 
interval (Table 4-2).  
Table 4-2.  Pregnant guinea pig grouping scheme 
Group Treatment Guinea Pigs (n) Trial 1 Trial 2 Total 
I No Lbc (Negative Control) 2 2 4 
II No Lbc + Lm 3 3 6 
III LbcWT + Lm 3 4 7 
IV LbcLAPLm + Lm 3 3 6 
V LbcLAPLin + Lm 4 4 8 
 
Probiotics (9 ? 109 cfu/ml, 50 ml/animal) were prepared fresh daily by pelleting 
an overnight probiotic culture by centrifugation (8000 ?g for 10 min) and washing the 
cells in sterile water.  Washed cells were then pelleted again (8000 ?g for 10 min) and 
resuspended in 50 ml of sterile water.  Probiotics were supplied to guinea pigs through a 
bottle daily for 17 days (9 ? 109cfu/ml).  All guinea pigs consumed a minimum of 35 ml 
of water per day. Guinea pigs that refused to consume food, water, or both were syringe 
fed needed sustenance three times daily.  For L. monocytogenes challenge, overnight 
grown L. monocytogenes was mixed with sterile cream sweetened with Splenda (5 
mg/ml) at a concentration 9 ? 108 cfu/ 2 ml for trial 1 and 2.5 ? 109 cfu/ 2 ml for trial 2.  
  
86  
To desensitize guinea pigs to the stress of syringe feeding, for the three days preceding 
the challenge, animals were syringe fed 2 ml of sweetened cream.  On day 14, animals 
were syringe fed a sub-clinical dose, 9 ?108 cfu/animal for trial 1 and 2.5 ? 109 
cfu/animal for trial 2 of L. monocytogenes F4244 prepared in 2 ml of sweetened cream.  
Animals were sacrificed 72 h post challenge via barbiturate overdose and maternal 
(intestines, liver, spleen, mesenteric lymph nodes (MLN), kidney, lungs, placenta and 
blood) and fetal tissues (liver and brain) were collected.  Blood was collected post 
sacrifice using a cardiac puncture.  Pieces of organs (approximately 1 g) were 
homogenized in 9 ml of PBS using a tissue homogenizer (Cole Parmer, Vernon Hills, IL) 
or stomached using a stomacher in sterile PBS.  Samples were serially diluted in sterile 
PBS and plated on MRS agar (for Lbc enumeration) and TSBYE agar containing MOX 
Listeria supplement (Neogen) (for L. monocytogenes enumeration) the same day.  When 
no L. monocytogenes colonies were observed on MOX plates, samples (500 μl of tissue 
homogenates) were immediately transferred to 3 ml Frasier Broth (BD) and incubated at 
37oC for 24 h.  The positive Frasier Broth cultures were determined by the presence of 
black pigment in the broth and were plated on MOX plates (Neogen).  Three colonies per 
MOX plate were confirmed as L. monocytogenes by amplifying prfA gene by 




done using a thermocycler (GeneAmp PCR System 9700, Applied Biosystems) as 
follows in table 4-3.   
Table 4-3.  PCR conditions for amplification of prfA 
 Temperature (oC) Time Cycles 
Initial Denaturation 95 5 min 1 
Cycles   30 
    Denaturation 95 60 s  
    Annealing 54 60 s  
    Extension 72 90 s  
Final Extension 72 10 min 1 
 
The amplified DNA was resolved in 1.2% agarose gel and visualized by ethidium 
bromide staining with a ChemiDoc XRS gel documentation system (Bio-Rad). 
 
4.2.4.? Serum cytokine quantification 
Serum IL-6, TNF-?, and TGF-?1 were quantified using RayBio Human ELISA 
Kits ELH-IL6, ELH-TNFa, and ELH-TGFb1 (RayBiotech, Norcross, GA), respectively, 
using manufacturer instructions.  Briefly, TGF-?1 required activation before 
quantification which was accomplished by adding 0.1 ml of 2.5 N Acetic acid/10 M Urea 
per 0.1 ml of serum, incubated at room temperature for 10 min and 0.1 ml 2.7N 
NaOH/1M HEPES per 0.1 ml of serum to neutralize acidified serum.  Samples were used 
immediately.  IL-6 and TNF-? do not require activation.  Serum samples were diluted 
two fold with dilution buffer B (supplied in kit) and 100 μl of diluted serum was added to 
ELISA wells.  They were incubated at 4oC gently shaking for 16 h.  Each ELISA plate 
was immunoprobed with their respective biotinylated primary antibodies and at 
Streptavidin-Horse Radish Peroxidase conjugated secondary antibody for 1 h and 45 min, 
respectively.  Plates were developed using 100 μl TMB solution/well and incubated for 
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30 min at room temperature.  Stop solution (50 ul/well) was added and color 
development was measured at wavelength 450 nm using an Eposh Microplate 
Spectrophotometer (Biotek, Winooski, VT).  Cytokines were quantified using a standard 
curve as directed by the manufacturer.    
 
4.2.5.? Guinea pig serum cytokine array 
Within each treatment group, 50 μl of serum from each animal were pooled and 1 
ml of the mixed pooled sera was applied to semi-quantitative human inflammatory 
cytokine array membranes (AAH-CYT-1, Raybiotech Inc., Norcross, GA) overnight at 
4oC.  Human arrays were used because guinea pig specific arrays are not available.  
Moreover, guinea pigs have high homology with humans.  Immunoblotting was 
performed as per manufacturer instructions and the reaction intensity was quantified 
using NIH ImageJ software.  The background was subtracted from each datum point; 
they were normalized to array-specific positive controls and expressed as mean fold 
change.   
 
4.2.6.? Short chain fatty acid quantification from guinea pig feces 
The sort chain fatty acid (SCFA) content of feces and serum was performed at 
The Metabolite Profiling Facility, Bindley Bioscience Center at Purdue University.  Fecal 
pellets (100?mg/animal) were pooled within each group and homogenized in 900?μl of 
water and 1.4?mm ceramic beads per 100 mg of fecal pellets using a Precellys 24 
homogenizer.  Sera (100 μl/animal) were pooled within each treatment group and mixed 
by pipetting.  The pooled fecal homogenates or serum were labeled with regular aniline 
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(12C6), and external SCFA standard solution (10?mg/ml of acetic acid, propionic acid, and 
butyric acid) was labeled with aniline-13C6 using N-(3-Dimethylaminopropyl)-N?-ethyl 
carbodiimide hydrochloride (2?mg per sample). Crotonic acid (final 0.1?mg/ml) was used 
as an internal standard. The labeling mixture was incubated for 2?h, and triethylamine was 
added to stop the labeling reaction. Samples and standard reaction solutions were mixed 
(1:1) and analyzed with an Agilent 6460 Triple Quad LC/MS System (Agilent 
Technologies, Santa Clara, CA).  Fecal content was analyzed at day 0 and day 17 
(sacrifice) and SCFA were quantified (μg/mg).  Fecal SCFA data was represented in fold 
change between day 0 and day 17.  Endpoint serum (day 17) was analyzed for SCFA 
content. 
 
4.2.7.? Seroconversion of LAP 
Serum was pooled within each treatment group and antibodies against LAP and 
probiotics were analyzed using Western blot.  Recombinant LAP was purified from E. 
coli BL21 or ClearColi (Lucigen) using a Ni-affinity column. Recombinant LAP (5 
μg/well) was separated using SDS-PAGE (7.5% polyacrylamide) and transferred to 
hydrophobic, Immobilon-P membrane (Millipore, Billerica, MA).  Membranes were 
immunoprobed using 100 μl of pooled sera diluted in sterile PBS (1:50) and incubated at 
4oC overnight (12-16 h).  A secondary, anti-guinea pig antibody conjugated with 
Horseradish Peroxidase (Cat. No. A18769, Life Technologies), 0.5 μg/ml was used and 
developed using 3,3'-Diaminobenzidine (DAB) or LumiGLOW chemiluminescent 




4.2.8.? Quantification of total serum cholesterol 
Total serum cholesterol was quantified using Amplex Red Cholesterol Assay Kit 
(Thermo Fischer Scientific) by the manufacturer’s instructions.  Briefly, 5 μl of serum 
from each guinea pig was diluted tenfold using reaction buffer (supplied in kit) for a total 
volume of 50 μl.  The diluted serum was applied to a 96 well black microtiter plate (Cat. 
No. 437111, ThermoScientific) and 300 μl Amplex Red Reagent (supplied in kit) was 
added to each well.  The samples were incubated statically at 37oC for 30 min and 
flourometric measurements were taken using excitation wavelength of 544 nm and 
emission wavelength of 590 nm using a Spectramax Gemini EM (Molecular Devices, 
Sunnyvale, CA.  Total cholesterol quantities were calculated by manufacturer’s 
instructions.    
 
4.2.9.? Histopathology 
Guinea pig tissues were fixed in 10% neutral buffered formalin and embedded in 
paraffin. Sections (5 ?m thick) were stained with haematoxylin and eosin according to 
standard methods. Microscopic examination was performed by a board-certified 
veterinary pathologist and the interpretation was based on standard histopathological 
morphology. The pathologist was blinded to the treatment groups, and compared ileal, 
liver and lymph node sections to controls. To determine the extent of guinea pig ileal 
lesions, a semi-quantitative method was used that included the amount of inflammatory 
infiltrate and percentage of goblet cells comprising the villous epithelium. Similarly, 
guinea pig liver and mesenteric lymph node were evaluated based on extent of 
parenchymal necrosis and infiltrative inflammation.  A histomorphological scale for 
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assessing inflammation in the lamina propria of the mucosa is provided as follows: 3, 
marked amounts (sheets of granulocytes expanding the width of the villous tip); 2, 
moderate amounts (sheets of granulocytes at the base of the villous); 1, mild amounts 
(multifocal scattering); and 0, none seen. To estimate percentage of goblet cells, 
following scale was used: 3, 50% or greater; 2, 25-50%; 1, 11-25%; and 0, <10%. The 
higher the score, the more likely there is infection in the tissues.  
 
4.3? Results 
4.3.1? Recombinant probiotics persist only in the GIT 
For this probiotic vaccine to be an effective preventative against L. 
monocytogenes infection and possible damage to the fetus, it is imperative that the 
probiotic can persist in the gastrointestinal tract.  To assess probiotic colonization of the 
gut, fecal samples from each group were evaluated for the probiotic load on day 5 and 
day 10 of probiotic feeding.  We observed a 2-3 log increase in the probiotic supplied 
guinea pigs that was maintained across the two time points, suggesting that the probiotics 
were able to colonize and persist in the gut (Fig 4-2ab). We found no probiotics in any 
extraintestinal tissues. However, both wild type and recombinant probiotics were present 
in the intestinal tissues between 104-106 cfu/ml (Figure 4-2c).  These data support 





probiotics bacteria colonized the gut, indicating that LAP (from L. monocytogenes or L. 
innocua) expressing probiotic prevented L. monocytogenes interaction possibly through 
competitive exclusion. Moreover, no Lactobacillus was found in extraintestinal tissues 
suggesting that either probiotics expressing Listeria virulence protein not translocate 
across the epithelial barrier or if they did translocate they may have been cleared by the 






No maternal tissues displayed signs of inflammation.  The ileum of No Lbc 
supplied, control guinea pigs had variable length villi with few lymphocytes, plasma 
cells, and resident macrophages in the lamina propria. Lymphocytes and plasma cells also 
filled the lamina propria at the base of the mucosa.  Goblet cells were mostly confined to 
the intestinal crypts. Goblet cells comprised less than 10% of the villous epithelium.  No 
guinea pigs treated with probiotics and challenged with L. monocytogenes showed any 
signs of an increase in inflammatory cells such as heterophils, lymphocytes, and 
macrophages.  Regardless of the challenge, enterocytes were intact with no necrosis.  All 
livers had mild numbers of lymphocytes and occasionally plasma cells surrounding the 
portal areas of the liver, and was considered background lesion and not related to the 
challenge.  No lymph nodes had a focal abscess or increased number of heterophils.  






4.3.4? Short chain fatty acid (SCFA) content in guinea pig feces 
Here we observed that L. monocytogenes induced a drastic reduction in all SCFAs 
in fecal content.  Treatment groups supplemented with LbcWT and the recombinant 
probiotics helped to rescue the SCFA content.  Interestingly, LbcLAPLin showed a 5-fold 
increase in butyric acid compared to the No Lbc control.  Taken together, these data 
suggest that L. monocytogenes has a negative effect on SCFA content and that both 
LbcWT and the recombinant probiotics, despite the pregnant background can help to 





4.3.5? Probiotic modulation of serum cytokines 
Probiotics are known to exert modulation over host cytokine secretion and 
maintain acute immune homeostasis with regard to commensal intestinal microbiota 
through NF-?B mediated TNF-a secretion from the host epithelium (Ma et al, 2014; 
Pagnini et al 2010).  Previously we have observed in in vitro Caco-2 and in vivo healthy 
A/J mice that the recombinant probiotics negated Lm induced epithelial secretion of 
TNF-? and IL-6 (Drolia et al., in preparation; Amalaradjou et al, in preparation).   L. 
monocytogenes challenged animals that either not fed probiotics or fed WT showed a 
significant (p < 0.001) increase in serum IL-6, while recombinant probiotic fed animals 
were not significantly (p = 0.2) different from No Lbc control animals. TGF-?1 in, 
LbcLAPLm and LbcLAPLin supplemented animals were significantly (p < 0.05) lower 
then both LbcWT and control challenged animals. TGF-?1 has also been shown to be 
associated with differentiation of Th17 cells (Eisenstein and Williams 2009).   TNF-?, 





 MCP-1 levels were elevated in both the Lm challenge and LbcWT groups, while 
the recombinant probiotic fed animals showed levels similar to control.  These data 
together suggest that recombinant probiotics can either directly or indirectly influence  
cytokine production possibly resulting in a decrease in L. monocytogenes induced 









L. monocytogenes is an invasive opportunistic intracellular human pathogen. It is 
ubiquitous and is transmitted primarily through food resulting in numerous fatal and 
costly outbreaks that are associated with consumption of contaminated cheese, ice cream, 
smoked fish, ready-to-eat meats, and produce (cantaloupe, apples, spinach) (Marquis et 
al. 2016).  L. monocytogenes can penetrate the blood-brain and blood-placental barrier, 
and as such listeriosis, the disease associated with L. monocytogenes infection typically 
manifests as sepsis or meningitis in high-risk individuals (Sacco et al. 2016).  Because of 
its opportunistic nature, listeriosis is not typically associated with healthy adults, but 
rather immune compromised individuals including the very young, elderly, individuals on 
immunosuppressive drugs such as cancer patient or organ transplant recipients, HIV-
AIDS patients and pregnant women (Sleator et al. 2009; Xayarath and Freitag 2012).  
Pregnant women exposed to L. monocytogenes typically experience flu-like symptoms; 
however, L. monocytogenes associated pregnancy complications include abortion, 
stillbirth, premature birth, and infants with L. monocytogenes infections.  When L. 
monocytogenes breaches the blood-placental barrier and the infant is alive at birth the 
child has symptoms of listeriosis at birth and is referred to as early-onset listeriosis; 
however, if the infant becomes infected during birth, listeriosis symptoms typically 
manifest two weeks after birth and is known as late-onset listeriosis (Bhunia 2008).   
According to a global study conducted in 2010, the mortality rate of L. 
monocytogenes infection is 22.4% (Kirk et al. 2015).  Pregnancy-associated infection 
accounts for 17% of total L. monocytogenes infections in the united states and of those 
infections 20.3% resulted in fetal loss, 32.9% resulted in infant meningitis, and 36.5% 
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resulted in infant sepsis (Jackson et al. 2010).  Despite the high mortality rate and 
economic healthcare burden of L. monocytogenes infection, there is currently no vaccine 
or prophylactic medical intervention for L. monocytogenes.  Rather, the CDC outlines a 
physical prophylactic intervention by thoroughly cooking all meats, safe food handling, 
and avoiding FDA designated high-risk foods including ready-to-eat meats, 
unpasteurized dairy products, smoked fish, etc.  The development of a preventive 
intervention of listeriosis is imminently needed and would have a substantial public 
health impact.  Probiotics have become an attractive vaccine vector for foodborne 
pathogens for several reasons including their ability to persist in the gut, general 
promotion of gut health, and they are generally regarded as safe (GRAS) (Amalaradjou 
and Bhunia 2012; Sanders et al. 2014).  Probiotics produce antibacterial peptides and 
macromolecules that negatively impact pathogenic bacteria, while directly and indirectly 
modulating host cytokine production to promote overall gut health and homeostasis (Cho 
et al. 2014).  Lactobacillus casei is a probiotic, lactic acid bacteria that displays many of 
these attributes such as persistence in the gut and enhancement of gut barrier integrity 
(Amalaradjou and Bhunia 2012).  One key drawback is that probiotic health benefits have 
been shown to be strain specific and unpredictable and have had limited success 
mitigating L. monocytogenes infection (Culligan et al. 2009) 
We have shown that LAP is an important L. monocytogenes virulence factor 
associated with promotion of paracellular translocation and dissemination of the pathogen 
(Burkholder et al. 2010, Drolia et al. In preparation).  We have also shown that LAP from 
pathogenic L. monocytgenes and non-pathogenic L. innocua are highly homologous.  
Moreover, pathogenicity of LAP deficient L. monocytogenes can be rescued by non-
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pathogenic LAP from L. innocua, suggesting that these two proteins may be 
interchangeable (Jagadeesan et al. 2010; Jagadeesan et al. 2011).  This interchangeability 
of LAP and the need for prophylactic listeriosis intervention prompted our lab to develop 
a recombinant Lactobacillus casei expressing LAP from either the pathogen (LbcLAPLm) 
or non-pathogen (LbcLAPLin).  In previous in vitro Caco-2 and in vivo mouse studies, we 
found that both recombinant probiotics are equally protective against clinical L. 
monocytogenes infection.  This inevitably raised the question, are these recombinant 
probiotics protective against L. monocytogenes infection in an immunocompromised 
model such as pregnancy? 
To investigate the protective nature of these Lbc against L. monocytogenes 
infection in pregnant individuals an appropriate animal model must be selected.  Mice 
were adequate in previous studies; however, the differences in placental structure 
between humans and mice is too high to make them comparable (Hashino et al. 2015).  
Moreover, due to a single amino acid substitution in mice and rats E-cadherin the InlA/E-
cadherin interaction does not take place (Lecuit et al. 1999; Lecuit 2007).  Guinea pigs 
have been used for many years as a pregnant and non-pregnant model for Listeria 
pathogenesis (Bakardjiev et al. 2004).  Guinea pigs are a InlA permissive species (Lecuit 
2007) and are the rodent that shares the most placental similarity with humans, 
particularly the barrier and interaction between the dam and fetal tissues during 
development (Mess and Carter 2007).  Both species have a discoidal placenta; 
trophoblasts invade the uterus into the endometrium, and inner third of the myometrium, 
and the maternal blood spaces are lined by one layer of trophoblasts during the later 
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stages of pregnancy (Leiser and Kaufmann 1994; Disson et al. 2008; Schmidt et al. 
2015).  
In humans, the fetal gestational period is nine months, with three distinct 
development periods divided into three-month long trimesters (Kaur et al. 2007).  Due to 
increased immune suppression and a thinning of the trophoblast lining of the feto-
placental barrier, L. monocytogenes is most infective during the third trimester of human 
pregnancy (Robbins et al. 2010).  Pregnant guinea pigs were supplied probiotics for 17 
days and challenged with L. monocytogenes during the last 20 days of their 60-day 
gestational period (Paavola 1979), the equivalent of the human third trimester.  The orally 
supplied L. monocytogenes is sufficient for intestinal colonization, but not always clinical 
presentation in non-pregnant guinea pigs is 108-1010 cfu/animal (Melton-Witt et al. 2012).  
An orally administered dose for 50% fetal infection in pregnant guinea pigs is 104-108 
cfu/dam; however, this may not be enough for clinical infection of the dam (Williams et 
al. 2011).  Pregnant guinea pigs orally dosed with 9 ? 108 or 4.5 ? 109 cfu/animal showed 
not physical characteristics of clinical infection in dams; however, challenged control 
animals (No Lbc + Lm) showed 100% L. monocytogenes dissemination to the placenta 
and 50% dissemination to the fetal liver.  These data suggest that, though the dose of L. 
monocytogenes administered was not sufficient for clinical listeriosis in the dam, it was 
sufficient for fetal infection.  Amazingly, these recombinant probiotics reduced 
dissemination to extraintestinal tissues like the liver, spleen, and mesenteric lymph node 
and completely mitigated dissemination to the lungs and kidney.  Recombinant probiotic 
supplemented animals did not showed the presence of L. monocytogenes in the placenta 
  
113  
and fetal liver, while both the No Lbc and LbcWT treated animals 100 and 25% positive, 
respectively; however, no fetal brains were positive. 
Probiotics are known to induce cytokine production to reduce inflammation and 
maintain gut homeostasis (Ng et al. 2009).  Pro-inflammatory cytokine IL-6 is an 
essential regulatory protein for acute inflammation.  It is responsible for recruitment of 
monocytes and neutrophils post L. monocytogenes infection (Scheller et al. 2011) and has 
recently been linked to differentiation of CD4+ T cells to primary pro-inflammatory Th17 
cells (Bettelli et al. 2006; Simone et al. 2015).  Additionally, TGF-?1 has also been 
shown to be associated with differentiation of  Th17 cells (Eisenstein et al. 2009; Li et al. 
2006).  We have previously shown in non-pregnant mice that through activation of NF-
?B, both intestinal and sera levels of TNF-? and IL-6 were increased during L. 
monocytogenes infection resulting in destabilization of the epithelial barrier and increased 
extraintestinal translocation of L. monocytogenes; however, supplementation of 
LbcLAPLm and LbcLAPLin decreased L. monocytogenes induced TNF-? and IL-6.  Here 
we observed the same trend in our pregnant guinea pig model, and showed that serum 
TNF-? and IL-6, as well as TGF-1 levels, are reduced by the supplementation of 
recombinant probiotics.  This suggests that the recombinant probiotics both help maintain 
gut homeostasis and mitigate L. monocytogenes induced cytokine stimulation; however, it 
is unclear if the probiotic regulation of cytokines is direct, resulting from interaction with 
host epithelial cells or indirect, resulting from the production of a metabolite such as 
SCFA which interacts with host cells.  It is important to note that the reduction in 
proinflammatory cytokines could simply be a result of less interaction and invasion of 
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host epithelial or immune cells by L. monocytogenes.  We suppose that it is a 
combination of the three.   
Short chain fatty acids (SCFAs; acetic, propionic and butyric acids) are known to 
enhance the intestinal epithelial integrity and overall gut health through maintenance of 
tight junction proteins (Elamin et al. 2013) and regulation of inflammation (Blaise et al. 
2007; Nancey et al. 2002; Tremaroli and Backhed 2012).   Moreover, in addition to their 
positive gastrointestinal health benefits, they are also able to negatively impact L. 
monocytogenes.  Butyrate has been shown to affect both membrane composition and 
rigidity (Jolatok et al. 2010) and virulence gene transcription (Sun et al. 2012), while 
acetate, butyrate, and especially propionate can inhibit L. monocytogenes growth 
(Joloyok et al. 2010; Menconi et al. 2013).  Also, SCFAs have been shown to induce host 
epithelial cells to secrete antimicrobial peptides, such as bacteriocins (Amalaradjou and 
Bhunia 2012), which can also inhibit luminal pathogens.  In our previous study, we 
determined that L. monocytogenes were able to negativly impact SCFA synthesis 
significantly in healthy A/J mice.  While the probiotics were not able to enhance overall 
SCFA synthesis compared to the control.  LbcWT, LbcLAPLm, and LbcLAPLin were able 
to mitigate the adverse effect of L. monocytogenes (Amalaradjou  et al In Preparation).  
Here we have shown that both wild type and recombinant probiotics protect the host 
against L. monocytogenes inhibition of SCFA production in the gastrointestinal tract and 
this may serve as an important factor in the reduction of pathogen extraintestinal and fetal 
dissemination in pregnant hosts. Moreover, we have shown that the supplementation of 
probiotics has general health benefits like the reduction of total serum cholesterol, which 
could serve to protect the host against heart disease and heart attack. 
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In summary, we have shown that recombinant LAP expressing probiotics protect 
against extraintestinal dissemination to both the dam and the fetus, decreased pro-
inflammatory cytokines, decreased L. monocytogenes mediated adverse SCFA effect, and 
positively influenced general health.  Importantly, we showed that the recombinant 
probiotic expressing non-pathogenic LAP was just as affective at these attributes and 
more effective at lowering serum cholesterol, negating the need to use any pathogenic 
factors and providing a “feel good” factor to potential consumers that a product 
containing a pathogenic virulence factor cannot.  This probiotic vaccine could potentially 
provide much needed protection and relief to high-risk groups, including pregnant 
women and their fetuses against listeriosis.  Moreover, this research suggests an exciting 
platform for possible prevention of many other foodborne pathogens, such as diarrheal 
disease-causing pathogens like Salmonella, which is of grave concern in the developing 
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Within the research done in this thesis purified Listeria adhesion protein (LAP) and 
glyceraldehyde phosphate dehydrogenase (GAPDH).   
 
Methods 
Bacterial Strains and Growth Conditions 
E. coli BL21 secreting His-tagged GAPDH (clones 1-10) were grown in 500 ml of Luria-
Bertani broth (LB, 0.5% NaCl, 1% tryptone peptone, and 0.5% yeast extract) containing 
ampicillin (100 μg/ml)  at 37°C for 3 h and transferred to room temperature and grown 
for 13-15 h.  Cultures were shaken (120 rpm/min) during the entire 16-18 h of growth.   
 
Selection of E. coli BL21 secreting His-tagged GAPDH clone 
Each clone was grown by the conditions stated above.  Bacterial cells were pelleted by 
centrifugation at 6,000 xg for 10 min at 4oC.  Cells were washed with sterile PBS and 
pelleted by centrifugation again at 6,000 xg for 10 min at 4oC.  Washed cells were 
suspended in cell 2X sample solvent (0.5 M Tris-Hcl, pH 6.8 4% SDS, 0.3 M ?-
mercaptoethanol) and sonicated on ice for 3 cycles of 15 s sonication and 15 s rest.  Pellet 
cell debris by centrifugation at 8000 xg for 3 min.  Protein containing supernatant sample 




pump.  Beads were equilibrated with 30 ml (6 bead volumes) binding buffer supplied in 
His Binding Kit (5 ml/min).  Sample (40 ml) was applied to the column at 0.5 ml/min.  
Binding buffer supplied in His Binding Kit (30 ml) was applied to the column (0.5 
ml/min) after sample was applied.  Beads were washed with 30 ml of wash buffer 
supplied in His Binding Kit (5 ml/min).  Bound His-tagged proteins were eluted from the 
column by adding 30 ml of elution buffer supplied in His Binding Kit at 0.5 ml/min, 
while collecting 0.5 ml fractions.  Protein content of each collected fraction was 
quantified by NanoDrop 1000 (Wilmington, DE) and fractions containing proteins were 
pooled. 
 
Desalting with HiTrap Desalting column and Protein Storage 
Pooled fractions were applied to a 5 ml HiTrap Desalting column (GE) in 5 ml fractions.  
Proteins were desalted and eluted by adding sterile PBS to the column 0.5 ml/min) while 
0.5 ml fractions were collected.  Proteins were eluted until fractions containing no protein 
are collected.  Protein quantified by NanoDrop 1000.  Desalted proteins were stored in 





Appendix B.  Interaction between rLAP and rGAPDH using an overlay assay 
 
Introduction 
The Listeria Adhesion Protein (LAP: 104 kDa) has been identified as a noncanonical L. 
monocytogenes virulence factor. LAP is a bacterial bifunctional alcohol acetaldehyde 
dehydrogenase (Aad) enzyme encoded by lmo 1634 gene that can be identified 
intracellularly, in the cell wall, and is secreted from L. monocytogenes (Kim et al. 2006).  
Cytoplasmically, LAP is a housekeeping enzyme participating in the anaerobic glycolytic 
process which also acts as an adhesion factor in L. monocytogenes. By comparing LAP 
amino acid sequence with existing protein databases, LAP was identified as a bi-
functional enzyme which consists of an N terminal NAD dependent aldehyde 
dehydorgenase (ALDH) and a C terminal alcohol dehydrogenase (ADH) domain 
(Jagadeesan et al. 2010).  LAP also moonlights as an extracellular adhesion protein that 
interacts with host intestinal Hsp60 (Wampler et al. 2004).  LAP is secreted through the 
alternate secretory pathway SecA2 and re-associates with the bacterial cell through a 
mechanism currently being elucidated (Burkholder et al. 2010).  It has been postulated 
that LAP possibly binds to cell wall expressed glyceraldehyde dehydrogenase (GAPDH) 
(unpublished).  To investigate this an overlay assay was performed. 
 
Materials and Methods 
Overlay Assay.  Recombinant GAPDH (rGAPDH) and LAP were nickel column purified 
(see Appendix A for method) and separated using SDS-PAGE (7.5% acrylamide).  
Protein was transferred to a hydrophobic membrane.  rGAPDH lanes were excised from 
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the membrane and allowed to interact with rLAP (10 μg/ml) in PBS for 12 h at 4oC.  
Membrane was washed using sterile PBS-T (0.1% Tween-20) and immunoprobed with 
anti-LAP mAb (0.5 μg/ml) for 2.5 h at room temperature with gentle agitation.  
Membrane was washed and probed with secondary HRP conjugated anti-mouse  Ab 
(0.25 μg/ml) for 1h. with at room temperature with gentle agitation.  Blot was developed 
using chemiluminescent substrate (cell signaling) and visualized on film.  Controls were 
used to establish that the anti-LAP mAb has no affinity for rGAPDH, while having 
affinity for rLAP. 
 
Results and discussion 
We observe that there was interaction between rGAPDH and rLAP in the overlay assay.  
Banding can be seen at 64 kDa using the anti-LAP antibody suggesting that rLAP bound 
to rGAPDH on the membrane.  It was clearly seen that anti-LAP mAb does not interact 
with rGAPDH, while showing strong interaction with rLAP.  These data suggest that a 





Appendix C.  Anti-GAPDH antibody has no affinity for native GAPDH 
 
Materials and method 
Total protein extraction from L. monocytogenes and L. innocua 
Listeria cultures were grown in Tryptic soy broth containing 0.6% yeast extract (TSBYE) 
for 16-18 h at 37oC shaking.    Bacterial cells were pelleted by centrifugation at 6,000 xg 
for 10 min at 4oC.  Cells were washed with sterile PBS and pelleted by centrifugation 
again at 6,000 xg for 10 min at 4oC.  Washed cells were resuspended in cell 2X sample 
solvent (0.5 M Tris-Hcl, pH 6.8 4% SDS, 0.3 M ?-mercaptoethanol)and sonicated on ice 
for 3 cycles of 15 s sonication and 15 s rest.  Pellet cell debris by centrifugation at 8000 
xg for 3 min.  Protein containing supernatant sample was retained and quantified using a 
BCA kit (Thermo Scientific). 
 
Western Blot  
L. monocytogenes and L. innocua total protein (25 μg/well) and rGAPDH (5 μg/well) 
were separated by SDS-PAGE  and transferred to a hydrophobic membrane.  Membrane 
was immunoprobed by anti-GAPDH pAb (1 or 2 μg /ml).  A secondary HRP conjugated 
anti-mouse Ab was used.  Bands were developed using chemiluminescent substrate (Cell 
Signaling) and developed on film 
 
Results 
The anti-GAPDH antibody showed no affinity to native GAPDH from L. monocytogenes 








Anti-GAPDH antibody that was developed by a previous lab member only shows affinity 
for the recombinant GAPDH that it was developed from; however; it has no affinity for 
native GAPDH from Listeria.  For further analysis of GAPDH as a candidate cell wall 
anchor for LAP an antibody must be developed that has affinity for both native and 
recombinant GAPDH from L. monocytogenes.  Here we show the development of this 
antibody. 
 
Materials and Methods 
Total protein extraction 
Listeria monocytogenes F4244 culture were grown in Tryptic soy broth containing 0.6% 
yeast extract (TSBYE) for 16-18 h at 37oC shaking.    Bacterial cells were pelleted by 
centrifugation at 6,000 xg for 10 min at 4oC.  Cells were washed with sterile PBS and 
pelleted by centrifugation again at 6,000 xg for 10 min at 4oC.  Washed cells were 
resusdpended in cell 2X sample solvent (0.5 M Tris-Hcl, pH 6.8 4% SDS, 0.3 M ?-
mercaptoethanol) and sonicated on ice for 3 cycles of 15 s sonication and 15 s rest.  Pellet 
cell debris by centrifugation at 8000 xg for 3 min.  Protein containing supernatant sample 
was retained and quantified using a BCA kit (Thermo Scientific). 
Western blot showing affinity of anti-GAPDH antibody L. monocytogenes  total protein 






Appendix G.  Fecal DNA extraction and 16S rRNA amplification for microbiome 
 
 
Extraction of DNA from feces for microbiome analysis 
Fecal DNA was extracted using a MP Biomedicals FastDNA Spin Kit for Soil (Cat. No. 
116560200, Santa Ana, CA) following the manufacturer’s instructions.  Briefly, 50 mg of frozen 
feces was applied to a Lysing matrix E tube from each mouse and 978 μl of sodium phosphate 
buffer was added.  Feces was disrupted using a MP Biomedical FastPrep bead beater (Santa Ana, 
CA) at speed 5.5 for 30 s.  Fecal debris was pelleted by centrifugation at 14,000 rpm for 5 min.  
Supernatant was transferred to a clean 1.5 ml microcentrifuge tube and 250 μl of protein 
precipitation solution (PPS) was added.  Tubes were inverted 30 times to mix.  Precipitated 
protein was pelleted by centrifugation at 14,000 rpm for 5 min.  Supernatant was transferred to a 
clean 2 ml tube.  Mix Binding Matrix (900 μl) was added to the supernatant and thoroughly 
mixed by inverting for 2 min by hand.  Mix was incubated for 3 min at room temperature.  All 
beads that settled were resuspended by inversion.  Mix was added 600 μl at a time to the Spin 
Column and centrifuged for at 14,000 rpm for 1 min until samples were fully processed through 
the Spin Column.  DNA bound to the matrix of the spin column was washed twice with 500 μl of 
SEWS buffer.  SEWS buffer was pulled through the matrix by centrifugation at 14,000 rpm for 1 
min.  Tubes were centrifuged for an additional 2 min at 14,000 rpm to ensure all SEWS buffer 
was removed.  DNA was eluted from the SPIN column to a clean capture tube by passing 50 μl 
of DES solution through the Spin Column by centrifugation at 14,000 rpm for 2 min.  All DNA 





16S rRNA PCR of mouse fecal DNA for Microbiome Analysis 
 
Primary PCR master mix was prepared mixing the items in the table 3-X with template 
DNA in a 96 well PCR plate.  16S rRNA was amplified between variable regions 3 and 4.  The 





Table F-1.  16S Primary PCR Master Mix 
Reagent Stock Concentration Vol./ reaction (μl) Vol./ 96 well plate (μl) 
PCR Water ---- 21.25 2125 
BSA 2% 1.25 125 
Q5 Master Mix 2X 25.00 2500 
F Primer 25 μM 0.75 75 
R Primer 25 μM 0.75 75 
DNA Template 5 ng/μl 1.00 Do Not Add 
Total vol.  50.00 4900 
 
PCR was run using conditions in Table F-2.   
 
Table F-2.  Primary PCR conditions 
 Temperature (oC) Time Cycles 
Initial Denaturation 95 5 min 1 
Cycles   15 
    Denaturation 94 30 s  
    Annealing 58 20 s  
    Extension 72 20 s  
Final Extension 72 10 min 1 
 
Axygen AxyPrep Mag PCR product clean-up 
PCR products from primary PCR were centrifuged at 1000 xg for 1 min.  Using a 
multichannel pipette, 90 μl of Axygen AxyPrep Mag (Cat. No. 14-223-152, Fisher Scientific) 
beads was added to each well.  Samples were mixed by pipetting for 10 min.  and incubated at 
room temperature for 5 min.  Beads were separated by placing 96 well PCR-plate on SPRI 
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magnet for 2 min.  Supernatant was removed by pipetting while leaving the plate on the magnet.  
Beads were washed twice with 200 μl of 70% ethanol to each well and air dried for 15 min.  























Purdue University, West Lafayette, Indiana                                     Expected: Dec 2016 
Master of Science in Molecular Food Microbiology   
 
Purdue University, West Lafayette, Indiana                                                        Aug 2013 
Bachelor of Science in Genetics and Microbiology                                                                                    
 
Ivy Tech Community College, Lafayette, Indiana                                             Jan 2013 
Biotechnology, non-degree seeking                                                                                                             
  
Experience  
Research Assistant, Purdue University Department of Food Science 2014-present 
Molecular Food Microbiology Lab. Working on recombinant probiotic vaccine protection 
against Listeria.  
•? Design and conduct animal studies and tissue and serum collection and analysis 
•? Cell culture including Caco-2, Vero, THP-1, RAW reporter cell studies 
•? Protein purification and interaction studies including chromatography, overlay assays, 
and ELISA  
•? Antibody development and purification 
•? Interdisciplinary collaboration with other labs, departments, and educational 
institutions 
•? Supervise and train two undergraduate students and a visiting Ph.D. 
•? Maintain detailed documentation of experiments, research and data.  
•? Interpret and analyze laboratory results. 
•? Prepare accurate and timely reports, publications, and oral presentations 
 
Substitute Instructor, Ivy Tech Community College                         Aug 2014-Aug 2016 
Biotechnology Department 
•? Designed and instructed lectures and laboratories regarding protein purification (SEC, 
AC, IEC, HPLC) 
•? Designed laboratory exercises teaching bacterial DNA extraction and RT-PCR 
amplification 
•? Guided laboratories regarding plasmid construction, cloning, and bacterial 
transformation 
•? Lectured on GMP, GLP, HACCP, and EPA/USDA/FDA regulation
  
155  
Laboratory Teaching Assistant, Purdue University                          Aug 2014-Dec 2015 
•? Demonstrated and taught general and advanced microbiology and molecular biology 
techniques. 
 
Research Associate, Purdue University, Bhunia Lab                      Aug 2013-Aug 2014 
Research Project: Listeria adhesion protein as an “affibac” for specific capture and 
detection of Listeria 
•? Use of molecular and microbiological techniques to elucidate the interaction between 
secreted virulence protein and bacterial cell wall anchoring protein. 
•? Expertise in protein purification using multiple chromatography techniques, including 
affinity, ion exchange, SE, and HPLC 
 
Biotechnology Technician, Ivy Tech Community College                  Feb 2011-Jan 2014 
•? Responsible for upkeep and maintenance of the biotechnology laboratory and 
equipment.  
•? Design and instruction laboratories in biotechnological and molecular techniques. 
•? Train new technicians in basic molecular and immunological techniques including 
PCR, Q-PCR, and Western Blot 
Skills 
•? Plasmid design, construction, and transformation 
•? DNA and protein extraction and amplification 
•? Immunoassay (Western, Dot Blot, ELISA)   
•? Multicolor flow cytometry 
•? Experience with BSL-2 pathogens 
•? Excellent problem solving, critical thinking and writing skills 
•? Teaching and training  
 
Awards 
•? Bernie J. Liska Outstanding Graduate Student Teaching Award                     
April 2016 




•? Ryan V.and A.K. Bhunia. 2017. Mitigation of foodborne disease infections by 
probiotics (prebiotics and synbiotics), In Foodborne Pathogens: Virulence 
Factors and Host Susceptibility. Editors: Gurtler, J.B., Doyle, M.P., Kornacki, J.L. 
Springer, New York, NY. ? 
 
Publications 
•? Ryan V, Bailey T, Vemulapalli, T et al. Recombinant Listeria Adhesion 
Protein Expressing Probiotics reduce extraintestinal dissemination of 
Listeria monocytogenes.  In Preparation 
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•? Amalaradjou, MA, Ryan, V, Drolia R, et al. Probiotic Lactobacillus expressing 
adhesion protein from a nonpathogenic bacterium protects mice against 
pathogen.  In Preparation 
•? Ansari, S., Bozkurt, F., Yazar, G., Ryan, V., Bhunia, A., & Kokini, J. (2015). 
Probing the distribution of gliadin proteins in dough and baked bread using 
conjugated quantum dots as a labeling tool. Journal of Cereal Science, 63, 41-48. 
•? Bozkurt, F., Ansari, S., Yau, P., Yazar, G., Ryan, V., & Kokini, J. (2014). 
Distribution and location of ethanol soluble proteins (Osborne gliadin) as a 
function of mixing time in strong wheat flour dough using quantum dots as a 
labeling tool with confocal laser scanning microscopy. Food Research 
International, 66, 279-288. 
 
Presentations 
•? “Health Beneficial Attributes of Bioengineered Probiotics Against Subclinical 
Infection of Listeria monocytogenes in Pregnant Guinea Pigs” IFT Annual Meeting 
and Food Expo. Chicago, July 18, 2016 
 
Posters 
•? “Recombinant Listeria Adhesion Protein Expressing Probiotics reduce 
extraintestinal dissemination of Listeria monocytogenes” Women’s Global Health 
Institute, Women’s Health Research at Purdue.  West Lafayette, IN November 10, 
2016 
 
•? “Recombinant Listeria Adhesion Protein Expressing Probiotics reduce 
extraintestinal dissemination of Listeria monocytogenes” CFSE Annual Research 
Planning Meeting. West Lafayette, IN, October 25, 2016   
 
•? “Health Beneficial Attributes of Bioengineered Probiotics Against Subclinical 
Infection of Listeria monocytogenes in Pregnant Guinea Pigs” CFSE Annual 
Research Planning Meeting. West Lafayette, In, November 16th, 2015 
